

Supporting Information
for Enantioselective [1,3] O-to-C Rearrangement: Dearomatization of Alkyl
2-Allyloxy/Benzyloxy-1/3-naphthoates Catalyzed by a Chiral π -Cu(II) Complex

Lu Yao and Kazuaki Ishihara*

Graduate School of Engineering, Nagoya University, B2-3(611), Furo-cho, Chikusa, Nagoya
464-8603, Japan

E-mail: ishihara@cc.nagoya-u.ac.jp


Contents

1. General Remarks	S2
2. General Procedure for the Synthesis of Ligands	S2
3. General Procedure for the Synthesis of Methyl 2-Allyloxy- and 2-Benzyloxy-1-naphthoates..	S6
4. General Procedure for Catalytic Asymmetric [1,3] Rearrangement of Methyl 2-Allyloxy- and 2-Benzyloxy-1-naphthoates	S13
5. Prospect for Appropriate Substrate and Optimization of the Reaction Conditions.....	S14
6. Spectral Characterization Data for the Products.....	S16
7. Synthetic Application of 2a	S24
8. X-ray Structure of Product (<i>S</i>)-2l and Cu(II) Complex	S26
9. References.....	S28
10. ¹ H NMR and ¹³ C NMR Spectra.....	S29
11. HPLC Chromatograms	S149

1. General Remarks


^1H NMR spectra were recorded on a JEOL ECS400 400 MHz spectrometer or a Bruker 500 MHz spectrometer in CDCl_3 . Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data are reported as (s = single, d = double, t = triple, q = quartet, m = multiple or unresolved, brs = broad single, coupling constant(s) in Hz, integration). ^{13}C NMR spectra were recorded on a JEOL ECS400 100 MHz or a Bruker 125 MHz spectrometer in CDCl_3 . Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm. Commercially obtained reagents were used without further purification. All reactions were monitored by TLC with silica gel-coated plates. Infrared (IR) spectra were recorded on a JASCO FT/IR 460 plus spectrometer. Enantiomeric ratios were determined by HPLC, using a chiralpak AS-3 column, chiralpak AD-3 column and chiralpak IA-3 column with hexane and *i*-PrOH as solvents. The racemic adducts were attained by using the complex of $\text{Cu}(\text{OTf})_2$ and racemic ligand as the catalyst. The absolute configuration of **21** was determined unequivocally according to the X-ray diffraction analysis, and those of other adducts were deduced on the basis of this result.

2. General Procedure for the Synthesis of Ligands



To a solution of *N*-(*tert*-butoxycarbonyl)-*L*-norvaline (1.08 g, 5.0 mmol) in dichloromethane (DCM, 25 mL) were added 1-hydroxybenzotriazole (HOBT, 743 mg, 5.5 mmol), DCC (1.10 g, 5.5 mmol) and butylamine (0.6 mL, 6.0 mmol) at 0 °C. Then the mixture was stirred at room temperature for 16 h before quenched with 10% w/w citric acid. After the mixture was filtered, the organic layer was separated and the aqueous layer was extracted with DCM. The combined organic layer was washed with brine, dried over Na_2SO_4 , filtered and then concentrated under reduced pressure. *tert*-Butyl (*S*)-(1-(butylamino)-1-oxopentan-2-yl)carbamate was obtained and directly used in next step without further purification.

To a solution of the crude *tert*-butyl (*S*)-(1-(butylamino)-1-oxopentan-2-yl)carbamate in DCM (6.4 mL) was added trifluoroacetic acid (TFA, 3.2 mL) dropwise at 0 °C. The mixture was then stirred at room temperature for 3 h. The mixture was neutralized with NaOH (1 *M*). The organic layer was separated, the aqueous layer was extracted with DCM. The combined organic layer was washed with brine, dried over Na_2SO_4 , filtered and then concentrated under reduced pressure. (*S*)-2-amino-*N*-butylpentanamide was obtained and directly used in next step without further purification.




To a solution of the crude (*S*)-2-amino-*N*-butylpentanamide and *N,N*-diisopropylethylamine (DIPEA, 1.0 mL, 6.0 mmol) in MeCN (20 mL) was added dibenzosuberone chloride (1.2 g, 5.25 mmol). The mixture was reacted at room temperature until the reaction completed (monitored by TLC). The reaction mixture was filtered through a pad of celite and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/hexane = 1/5, v/v) to afford the ligand **L8**.

(*S*)-*N*-Butyl-2-[(10,11-dihydro-5*H*-dibenzo[*a,d*][7]annulen-5-yl)amino]pentanamide (L8**):**

60% overall yield; white solid; m.p. = 89.1 °C; $[\alpha]_D^{23} = -15.9$ (*c* 1.00, CHCl₃); IR (film) 3304, 2957, 2929, 2871, 1644, 1552, 1445, 760 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.24 – 7.11 (m, 8H), 6.64 (s, 1H), 4.64 (s, 1H), 3.65 (m, 2H), 3.16 (dt, *J* = 20.1, 6.7 Hz, 1H), 3.08 – 2.96 (m, 4H), 1.66 (m, 1H), 1.57 – 1.53 (m, 2H), 1.39 – 1.26 (m, 6H), 0.91 (t, *J* = 7.2 Hz, 3H), 0.84 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): ¹³C NMR (125 MHz, CDCl₃) δ 174.3, 130.4, 130.3, 127.7, 127.6, 126.1, 125.9, 61.4, 38.5, 35.8, 32.8, 32.4, 31.5, 19.9, 19.0, 13.7, 13.6; HRMS (ESI+) *m/z* calcd. for C₂₄H₃₃N₂O: 365.2587, found: 365.2589.


The ligands used in screening were synthesized using the same procedure of synthesizing **L8**.

(*S*)-2-[(10,11-Dihydro-5*H*-dibenzo[*a,d*][7]annulen-5-yl)amino]-1-(pyrrolidin-1-yl)propan-1-one (L1**):**



57% overall yield; colorless viscous liquid; $[\alpha]_D^{25} = +59.3$ (*c* 0.71, CHCl₃); IR (neat) 2971, 2874, 1638, 1427, 764 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.34 (dd, *J* = 7.2, 1.6 Hz, 1H), 7.18 – 7.05 (m, 7H), 4.72 (s, 1H), 4.27 (brs, 1H), 3.61 – 3.47 (m, 3H), 3.13 (d, *J* = 6.6 Hz, 1H), 3.06 – 2.99 (m, 1H), 2.93 (t, *J* = 12.7 Hz, 1H), 2.87 – 2.81 (m, 1H), 2.75 (m, 1H), 2.27 (m, 1H), 1.85 – 1.82 (m, 4H), 1.13 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 130.7, 129.5, 127.6, 127.1, 125.6, 125.2, 52.1, 45.4, 45.3, 33.1, 31.3, 25.7, 23.9, 18.7; HRMS (ESI+) *m/z* calcd. for C₂₂H₂₇N₂O: 335.2118, found: 335.2110.


(*S*)-2-[(10,11-Dihydro-5*H*-dibenzo[*a,d*][7]annulen-5-yl)amino]-1-(pyrrolidin-1-yl)butan-1-one (L2**):**



54% overall yield; yellow viscous liquid; $[\alpha]_D^{26} = +57.8$ (*c* 0.71, CHCl₃); IR (neat) 2967, 2871, 1636, 1424, 762 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.33


(d, $J = 7.0$ Hz, 1H), 7.20 – 7.05 (m, 7H), 4.67 (s, 1H), 4.35 (brs, 1H), 3.63 – 3.47 (m, 3H), 3.08 – 2.74 (m, 5H), 2.17 (m, 1H), 1.85 (m, 4H), 1.47 (td, $J = 13.8, 6.9$ Hz, 2H), 0.89 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.3, 130.9, 129.6, 127.6, 127.2, 125.7, 125.2, 58.5, 45.5, 45.4, 33.2, 31.3, 26.5, 25.8, 24.0, 10.8; HRMS (ESI+) m/z calcd. for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}$: 349.2274, found: 349.2265.

(S)-2-[(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)amino]-3-methyl-1-(pyrrolidin-1-yl)butan-1-one (L3):




61% overall yield; white solid; m.p. = 89.8 °C; $[\alpha]_D^{26} = +74.3$ (c 0.71, CHCl_3); IR (film) 2956, 2871, 1637, 1492, 1422, 767 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.32 (d, $J = 6.8$ Hz, 1H), 7.18 – 7.03 (m, 7H), 4.58 (s, 1H), 4.46 (brs, 1H), 3.68 – 3.51 (m, 3H), 3.09 (dt, $J = 9.6, 6.8$ Hz, 1H), 2.91 – 2.72 (m, 4H), 2.23 (m, 1H), 1.89 – 1.84 (m, 4H), 1.71 (s, 1H), 0.93 – 0.82 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 173.2, 131.0, 129.6, 127.8, 127.3, 125.9, 125.3, 62.8, 45.9, 45.5, 33.4, 31.7, 31.2, 26.0, 24.2, 20.0, 18.4; HRMS (ESI+) m/z calcd. for $\text{C}_{24}\text{H}_{30}\text{N}_2\text{NaO}$: 385.2250, found: 385.2241.

(S)-2-[(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)amino]-1-(pyrrolidin-1-yl)pentan-1-one (L4):



63% overall yield; yellow viscous liquid; $[\alpha]_D^{27} = +49.8$ (c 0.71, CHCl_3); IR (neat) 2956, 2871, 1637, 1493, 1422, 768 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.34 (d, $J = 6.8$ Hz, 1H), 7.20 – 7.04 (m, 7H), 4.66 (s, 1H), 4.36 (brs, 1H), 3.63 – 3.50 (m, 3H), 3.06 – 2.84 (m, 4H), 2.73 (m, 1H), 2.21 (m, 1H), 1.84 – 1.78 (m, 4H), 1.51 – 1.27 (m, 4H), 0.75 (t, $J = 6.9$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 173.4, 130.8, 129.5, 127.6, 127.1, 125.7, 125.1, 56.4, 45.4, 45.3, 35.3, 33.2, 31.2, 25.8, 23.9, 19.0, 13.4; HRMS (ESI+) m/z calcd. for $\text{C}_{24}\text{H}_{30}\text{N}_2\text{NaO}$: 385.2250, found: 385.2247.


(S)-2-[(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)amino]-1-(pyrrolidin-1-yl)hexan-1-one (L5):



62% overall yield; yellow viscous liquid; $[\alpha]_D^{27} = +45.6$ (c 0.71, CHCl_3); IR (neat) 2952, 2865, 1638, 1421, 765 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.34 (d, $J = 6.9$ Hz, 1H), 7.20 – 7.05 (m, 7H), 4.67 (s, 1H), 4.37 (brs, 1H), 3.64 – 3.50 (m, 3H), 3.06 – 3.02 (m, 4H), 2.74 (m, 1H), 2.12 (m, 1H), 1.86 – 1.81 (m, 4H), 1.41 – 1.14 (m, 6H), 0.81 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 173.5, 130.9, 129.5, 127.6, 127.2, 125.8, 125.2, 56.8, 45.5, 45.4, 33.3, 33.0, 31.3, 28.1, 25.9, 24.0, 22.2, 13.8; HRMS (ESI+) m/z calcd. for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{NaO}$: 399.2407, found: 399.2398.


(S)-2-[(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)amino]-N-ethylpentanamide (L6):

58% overall yield; white solid; m.p. = 115.4 °C; $[\alpha]_D^{23} = -14.6$ (c 0.71, CHCl_3); IR (film) 3302, 2903, 2864, 2359, 1646, 1541, 761 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.24 – 7.11 (m, 8H), 6.61




(s, 1H), 4.64 (s, 1H), 3.67 (m, 2H), 3.15 (ddd, $J = 21.6, 13.8, 7.2$ Hz, 2H), 3.06 (dd, $J = 7.7, 5.0$ Hz, 1H), 2.96 (m, 2H), 1.95 (m, 1H), 1.69 – 1.62 (m, 1H), 1.53 – 1.50 (m, 1H), 1.40 – 1.24 (m, 2H), 1.03 (t, $J = 7.3$ Hz, 3H), 0.84 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 174.3, 130.5, 130.4, 127.8, 127.7, 126.2, 126.1, 61.7, 35.9, 33.7, 32.9, 32.6, 19.1, 14.7, 13.8; HRMS (ESI+) m/z calcd. for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{NaO}$: 359.2094, found: 359.2085.

(S)-2-[(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)amino]-N-propylpentanamide (L7):



61% overall yield; white solid; m.p. = 107.6 °C; $[\alpha]_{\text{D}}^{27} = -13.4$ (c 0.71, CHCl_3); IR (film) 3298, 2958, 2929, 2871, 1638, 1557, 1444, 1156, 761 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.22 – 7.11 (m, 8H), 6.66 (s, 1H), 4.65 (s, 1H), 3.64 (brs, 2H), 3.14 (td, $J = 13.4, 6.8$ Hz, 1H), 3.06 – 2.98 (m, 4H), 1.98 (m, 1H), 1.68 – 1.29 (m, 6H), 0.86 (dt, $J = 14.3, 7.3$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.4, 130.4, 130.3, 127.7, 127.6, 126.1, 126.0, 61.4, 40.5, 35.8, 32.8, 32.4, 22.7, 19.0, 13.7, 11.3; HRMS (ESI+) m/z calcd. for $\text{C}_{23}\text{H}_{30}\text{N}_2\text{NaO}$: 373.2250, found: 373.2241.


(S)-2-[(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)amino]-N-neopentylpentanamide (L9):



56% overall yield; white solid; m.p. = 108.3 °C; $[\alpha]_{\text{D}}^{28} = -13.6$ (c 0.71, CHCl_3); IR (film) 3313, 3061, 3016, 2957, 2869, 1651, 757 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.22 – 7.11 (m, 8H), 6.79 (s, 1H), 4.69 (s, 1H), 3.66 (m, 2H), 3.11 – 2.98 (m, 4H), 2.76 (m, 1H), 2.00 (m, 1H), 1.70 – 1.34 (m, 4H),

0.88 – 0.84 (m, 12H); ^{13}C NMR (125 MHz, CDCl_3) δ 174.4, 130.5, 130.4, 127.8, 127.7, 126.2, 126.1, 61.7, 50.1, 36.0, 32.9, 32.6, 31.5, 27.1, 19.1, 13.8; HRMS (ESI+) m/z calcd. for $\text{C}_{25}\text{H}_{34}\text{N}_2\text{NaO}$: 401.2563, found: 401.2558.


(S)-2-[(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yl)amino]-N-isopropylpentanamide (L10):



60% overall yield; white solid; m.p. = 114.0 °C; $[\alpha]_{\text{D}}^{24} = -11.2$ (c 0.71, CHCl_3); IR (film) 3301, 2964, 2873, 2360, 1639, 1543, 1456, 761 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.24 – 7.11 (m, 8H), 6.52 (d, $J = 7.6$ Hz, 1H), 4.63 (brs, 1H), 3.96 (ddt, $J = 13.1, 8.0, 6.6$ Hz, 1H), 3.68 (m, 2H), 3.03 –


2.97 (m, 3H), 1.94 (m, 1H), 1.69 – 1.63 (m, 1H), 1.51–1.49 (m, 1H), 1.36 – 1.29 (m, 2H), 1.10 (d, $J = 6.6$ Hz, 3H), 0.99 (d, $J = 6.6$ Hz, 3H), 0.84 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 173.5, 130.6, 130.4, 127.8, 127.7, 126.2, 126.0, 61.6, 40.6, 35.9, 32.9, 32.6, 22.8, 22.4, 19.1, 13.8; HRMS (ESI+) m/z calcd. for $\text{C}_{23}\text{H}_{30}\text{N}_2\text{NaO}$: 373.2250, found: 373.2251.

3. General Procedure for the Synthesis of Methyl 2-Allyloxy- and 2-Benzyloxy-1-naphthoates




The starting naphthols¹ (6 mmol) and Cs₂CO₃ (9 mmol) were dissolved in acetone (40 mL). Cinnamyl bromide² (or benzyl bromide) (8 mmol) was added by syringe and the reaction was heated to 60 °C until TLC revealed complete conversion of naphthols. The mixture was diluted with ethyl acetate and water after cooling. The organic layer was washed with brine, dried with anhydrous Na₂SO₄, and concentrated under vacuum. The residue was purified by silica gel chromatography to afford corresponding product.

Methyl 2-(cinnamyloxy)-1-naphthoate (**1a**):




1a was isolated by FC on silica gel using pentane/EtOAc 30:1; 86% yield; white solid; m.p. = 114.0 °C; IR (film) 2945, 1725, 1286, 1236, 756 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.88 (d, *J* = 9.1 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.76 (d, *J* = 8.5 Hz, 1H), 7.52 – 7.49 (m, 1H), 7.41 – 7.37 (m, 3H), 7.34 – 7.31 (m, 3H), 7.27 – 7.24 (m, 1H), 6.74 (d, *J* = 16.0 Hz, 1H), 6.41 (dt, *J* = 16.0, 5.6 Hz, 1H), 4.88 (dd, *J* = 5.5, 1.5 Hz, 2H), 4.04 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.3, 153.5, 136.3, 132.6, 131.5, 130.9, 128.6, 128.5, 128.0, 127.8, 127.5, 126.4, 124.2, 124.1, 123.8, 118.4, 114.8, 70.2, 52.3; HRMS (ESI+) *m/z* calcd. for C₂₁H₁₈NaO₃: 341.1148; found: 341.1146.

Methyl (*E*)-2-{{3-(*o*-tolyl)allyl}oxy}-1-naphthoate (**1b**):



1b was isolated by FC on silica gel using pentane/EtOAc 30:1; 78% yield; white solid; m.p. = 86.1 °C; IR (film) 3025, 2948, 1726, 1510, 1437, 1284, 1233, 809, 747 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.89 (d, *J* = 9.1 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.76 (d, *J* = 8.5 Hz, 1H), 7.50 (ddd, *J* = 8.4, 6.9, 1.2 Hz, 1H), 7.45 (dd, *J* = 5.3, 3.7 Hz, 1H), 7.38 (ddd, *J* = 8.0, 6.9, 1.1 Hz, 1H), 7.33 (d, *J* = 9.1 Hz, 1H), 7.18 – 7.13 (m, 3H), 6.97 (d, *J* = 15.8 Hz, 1H), 6.28 (dt, *J* = 15.8, 5.5 Hz, 1H), 4.90 (dd, *J* = 5.5, 1.6 Hz, 2H), 4.04 (s, 3H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 153.5, 135.5, 131.4, 130.9, 130.6, 130.2, 128.7, 128.0, 127.7, 127.5, 126.0, 125.7, 125.4, 124.2, 123.8, 118.4, 114.8, 70.3, 52.3, 19.6; HRMS (ESI+) *m/z* calcd. for C₂₂H₂₀NaO₃: 355.1305; found: 355.1298.


Methyl (*E*)-2-{{3-(*m*-tolyl)allyl}oxy}-1-naphthoate (**1c**):



1c was isolated by FC on silica gel using pentane/EtOAc 30:1; 67% yield; yellow liquid; IR (neat) 2941, 1727, 1510, 1283, 1235, 748 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.87 (d, *J* = 9.1 Hz, 1H), 7.79 (d,

$J = 8.2$ Hz, 1H), 7.76 (d, $J = 8.6$ Hz, 1H), 7.52 – 7.48 (m, 1H), 7.39 – 7.36 (m, 1H), 7.31 (d, $J = 9.1$ Hz, 1H), 7.22 – 7.20 (m, 3H), 7.08 – 7.06 (m, 1H), 6.71 (d, $J = 16.0$ Hz, 1H), 6.39 (dt, $J = 16.0, 5.6$ Hz, 1H), 4.87 (dd, $J = 5.6, 1.5$ Hz, 2H), 4.04 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 153.6, 138.1, 136.3, 132.9, 131.5, 131.0, 128.7, 128.4, 128.0, 127.5, 127.2, 124.3, 124.0, 123.8, 123.7, 118.4, 114.8, 70.4, 52.4, 21.3; HRMS (ESI+) m/z calcd. for $\text{C}_{22}\text{H}_{20}\text{NaO}_3$: 355.1305; found: 355.1303.


Methyl (*E*)-2-{{3-(*p*-tolyl)allyl}oxy}-1-naphthoate (1d**):**



1d was isolated by FC on silica gel using pentane/EtOAc 30:1; 83% yield; white solid; m.p. = 95.5 °C; IR (film) 2950, 1726, 1510, 1283, 1234, 754 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.87 (d, $J = 9.1$ Hz,

1H), 7.79 (d, $J = 8.2$ Hz, 1H), 7.76 (d, $J = 8.5$ Hz, 1H), 7.50 (t, $J = 7.6$ Hz, 1H), 7.38 (t, $J = 7.5$ Hz, 1H), 7.32 – 7.29 (m, 3H), 7.14 – 7.12 (m, 2H), 6.71 (d, $J = 16.0$ Hz, 1H), 6.35 (dt, $J = 15.9, 5.7$ Hz, 1H), 4.87 (dd, $J = 5.7, 1.4$ Hz, 2H), 4.04 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 153.6, 137.8, 133.6, 132.8, 131.5, 131.0, 129.3, 128.7, 128.0, 127.5, 126.4, 124.3, 123.8, 123.2, 118.5, 115.0, 70.6, 52.4, 21.2; HRMS (ESI+) m/z calcd. for $\text{C}_{22}\text{H}_{20}\text{NaO}_3$: 355.1305; found: 355.1297.


Methyl (*E*)-2-{{3-(4-bromophenyl)allyl}oxy}-1-naphthoate (1e**):**



1e was isolated by FC on silica gel using pentane/EtOAc 30:1; 83% yield; white solid; m.p. = 111.4 °C; IR (film) 2946, 1726, 1510, 1284, 1234, 748 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.88 (d, $J =$


9.1 Hz, 1H), 7.80 (d, $J = 8.2$ Hz, 1H), 7.76 (d, $J = 8.5$ Hz, 1H), 7.51 (t, $J = 8.3$ Hz, 1H), 7.45 – 7.43 (m, 2H), 7.39 (t, $J = 8.0$ Hz, 1H), 7.29 (d, $J = 9.1$ Hz, 1H), 7.27–7.25 (m, 2H), 6.68 (d, $J = 16.0$ Hz, 1H), 6.39 (dt, $J = 16.0, 5.4$ Hz, 1H), 4.87 (dd, $J = 5.4, 1.5$ Hz, 2H), 4.04 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.3, 153.4, 135.3, 131.7, 131.6, 131.4, 131.0, 128.8, 128.0, 128.0, 127.6, 125.1, 124.4, 123.8, 121.7, 118.5, 114.8, 70.1, 52.4; HRMS (ESI+) m/z calcd. for $\text{C}_{21}\text{H}_{17}\text{BrNaO}_3$: 419.0253; found: 419.0244.

Methyl (*E*)-2-{{3-(4-chlorophenyl)allyl}oxy}-1-naphthoate (1f**):**




1f was isolated by FC on silica gel using pentane/EtOAc 30:1; 73% yield; white solid; m.p. = 111.8 °C; IR (film) 2947, 1725, 1282, 1234 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.89 (d, $J = 9.1$ Hz, 1H),


7.80 (d, $J = 8.2$ Hz, 1H), 7.76 (d, $J = 8.5$ Hz, 1H), 7.51 (t, $J = 8.3$ Hz, 1H), 7.39 (t, $J = 8.0$ Hz, 1H), 7.33 – 7.28 (m, 5H), 6.70 (d, $J = 16.0$ Hz, 1H), 6.38 (dt, $J = 16.0, 5.5$ Hz, 1H), 4.88 (dd, $J = 5.5, 1.6$ Hz, 2H), 4.04 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.3, 153.4, 134.8, 133.4, 131.5, 131.3, 130.9, 128.7, 128.6, 128.0, 127.7, 127.6, 124.9, 124.3, 123.8, 118.4, 114.7, 70.0, 52.3; HRMS (ESI+) m/z calcd. for $\text{C}_{21}\text{H}_{17}\text{ClNaO}_3$: 375.0758; found: 375.0749

Methyl (*E*)-2-{{3-(naphthalen-1-yl)allyl}oxy}-1-naphthoate (1g):


1g was isolated by FC on silica gel using pentane/EtOAc 30:1; 48% yield; light yellow solid; m.p. = 136.3 °C; IR (film) 3095, 2951, 1726, 1510, 1284, 1234, 788 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.08 – 8.07 (m, 1H), 7.91 (d, *J* = 9.0 Hz, 1H), 7.86 – 7.77 (m, 4H), 7.61 (d, *J* = 7.0 Hz, 1H), 7.54 – 7.37 (m, 7H), 6.43 (dt, *J* = 15.7, 5.3 Hz, 1H), 5.00 (d, *J* = 4.4 Hz, 2H), 4.05 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 153.6, 134.2, 133.5, 131.6, 131.1, 131.0, 129.9, 128.8, 128.4, 128.2, 128.1, 127.6, 127.3, 126.1, 125.8, 125.5, 124.3, 123.9, 123.8, 123.7, 118.5, 114.8, 70.2, 52.4; HRMS (ESI+) *m/z* calcd. for C₂₅H₂₀NaO₃: 391.1305; found: 391.1296.

Methyl (*E*)-2-{{3-(naphthalen-2-yl)allyl}oxy}-1-naphthoate (1h):

1h was isolated by FC on silica gel using pentane/EtOAc 30:1; 53% yield; white solid; m.p. = 86.0 °C; IR (film) 3063, 2954, 1726, 1284, 1235, 787 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.90 (d, *J* = 9.1 Hz, 1H), 7.81 – 7.75 (m, 6H), 7.62 (d, *J* = 8.6 Hz, 1H), 7.51 (t, *J* = 8.0 Hz, 1H), 7.48 – 7.43 (m, 2H), 7.40 (t, *J* = 8.0 Hz, 1H), 7.35 (d, *J* = 9.1 Hz, 1H), 6.90 (d, *J* = 16.0 Hz, 1H), 6.54 (dt, *J* = 15.9, 5.5 Hz, 1H), 4.94 (dd, *J* = 5.5, 1.4 Hz, 2H), 4.06 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 153.6, 133.8, 133.5, 133.1, 132.8, 131.6, 131.0, 128.7, 128.2, 128.0, 127.9, 127.6, 127.5, 126.7, 126.3, 126.0, 124.6, 124.3, 123.8, 123.4, 118.4, 114.8, 70.4, 52.4; HRMS (ESI+) *m/z* calcd. for C₂₅H₂₀NaO₃: 391.1305; found: 391.1295.

Methyl (*E*)-2-{{3-(furan-3-yl)allyl}oxy}-1-naphthoate (1i):


1i was isolated by FC on silica gel using pentane/EtOAc 15:1; 46% yield; yellow viscous liquid; IR (neat) 2950, 1725, 1510, 1438, 1285, 1238, 751 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.88 (d, *J* = 9.1 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.50 (t, *J* = 7.1 Hz, 1H), 7.43 (s, 1H), 7.40 – 7.37 (m, 2H), 7.29 (d, *J* = 9.1 Hz, 1H), 6.61.6.54 (m, 2H), 6.13 (dt, *J* = 15.8, 5.6 Hz, 1H), 4.82 (dd, *J* = 5.6, 1.4 Hz, 2H), 4.04 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 153.6, 143.6, 140.8, 131.5, 131.0, 128.7, 128.0, 127.6, 124.3, 123.8, 123.7, 123.4, 122.8, 118.4, 114.9, 107.5, 70.3, 52.4; HRMS (ESI+) *m/z* calcd. for C₁₉H₁₆NaO₄: 331.0941; found: 331.0941.

Methyl (*E*)-2-{{3-(thiophen-3-yl)allyl}oxy}-1-naphthoate (1j):

1j was isolated by FC on silica gel using pentane/EtOAc 15:1; 47% yield; light brown solid; m.p. = 96.3 °C; IR (film) 2946, 1726, 1512, 1278, 1234 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.88 (d, *J* = 9.1 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.50 (t, *J* = 7.0 Hz, 1H), 7.38 (t, *J* = 7.0 Hz, 1H), 7.30 (d, *J* = 9.1 Hz, 1H), 7.29 – 7.27 (m, 1H), 7.23 – 7.22 (m, 1H), 7.19 – 7.18 (m, 1H), 6.74 (d, *J* = 15.9 Hz, 1H), 6.26 (dt, *J* = 15.9, 5.6 Hz, 1H), 4.85 (dd, *J* = 5.6, 1.5 Hz, 2H), 4.04 (s, 3H); ¹³C


NMR (125 MHz, CDCl₃) δ 168.4, 153.5, 138.9, 131.5, 130.9, 128.6, 128.0, 127.5, 127.0, 126.1, 124.9, 124.2, 124.0, 123.8, 122.7, 118.3, 114.8, 70.2, 52.3; HRMS (ESI+) m/z calcd. for C₁₉H₁₆NaO₃S: 347.0712; found: 347.0716.

Methyl (*E*)-2-[(3-phenylbut-2-en-1-yl)oxy]-1-naphthoate (1k):



1k was isolated by FC on silica gel using pentane/EtOAc 30:1; 85% yield; white solid; m.p. = 68.7 °C; IR (film) 2947, 1728, 1510, 1438, 1283, 1234, 756 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.88 (d, J = 9.1 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.50 (t, J = 8.3 Hz, 1H), 7.44 – 7.26 (m, 7H), 6.05 (t, J = 6.2 Hz, 1H), 4.93 (d, J = 6.2 Hz, 2H), 4.03 (s, 3H), 2.14 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 153.6, 142.4, 139.0, 131.4, 130.9, 128.6, 128.2, 128.0, 127.5, 127.4, 125.7, 124.2, 123.7, 122.6, 118.4, 114.8, 67.2, 52.3, 16.3; HRMS (ESI+) m/z calcd. for C₂₂H₂₀NaO₃: 355.1310; found: 355.1298.


Methyl 2-{[3,3-bis(4-chlorophenyl)allyl]oxy}-1-naphthoate (1l):



1l was isolated by FC on silica gel using pentane/EtOAc 30:1; 88% yield; white solid; m.p. = 105.8 °C; IR (film) 2950, 1729, 1491, 1283, 1235, 1091, 1014, 751 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.82 (d, J = 9.1 Hz, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.50 (t, J = 8.2 Hz, 1H), 7.40 – 7.37 (m, 3H), 7.27 – 7.24


(m, 2H), 7.16 – 7.13 (m, 4H), 7.07 (d, J = 9.1 Hz, 1H), 6.32 (t, J = 6.7 Hz, 1H), 4.73 (d, J = 6.7 Hz, 2H), 4.03 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 153.2, 143.9, 139.5, 136.7, 134.1, 134.0, 131.5, 131.0, 130.9, 128.9, 128.7, 128.5, 128.0, 127.6, 124.4, 124.4, 123.8, 118.7, 114.8, 67.5, 52.4; HRMS (ESI+) m/z calcd. for C₂₇H₂₀Cl₂NaO₃: 485.0682; found: 485.0687.

Methyl 2-[(3-methylbut-2-en-1-yl)oxy]-1-naphthoate (1m):



1m was isolated by FC on silica gel using pentane/EtOAc 30:1; 78% yield; yellow liquid; IR (neat) 2949, 1731, 1510, 1473, 1283, 1234, 1053, 810, 748 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.87 (d, J = 9.1 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.49 (t, J = 7.1 Hz, 1H), 7.37 (t, J = 7.1 Hz, 1H), 7.28 (s, 1H), 5.49 – 5.46 (m, 1H), 4.70 (d, J = 6.6 Hz, 2H), 4.02 (s, 3H), 1.77 (s, 3H), 1.74 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.4, 153.7, 137.7, 131.2, 130.9, 128.4, 127.9, 127.3, 124.0, 123.6, 119.6, 118.3, 114.9, 66.7, 52.1, 25.6, 18.0; HRMS (ESI+) m/z calcd. for C₁₇H₁₈NaO₃: 293.1148; found: 293.1150.


Methyl 6-bromo-2-(cinnamyloxy)-1-naphthoate (1n):



1n was isolated by FC on silica gel using pentane/EtOAc 30:1; 87% yield; a light brown solid; m.p. = 86.5 °C; IR (film) 2947, 1730, 1497, 1286, 1233 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.95 (d, J = 1.9 Hz,


1H), 7.79 (d, $J = 9.1$ Hz, 1H), 7.65 (d, $J = 9.1$ Hz, 1H), 7.57 – 7.55 (m, 1H), 7.41 – 7.26 (m, 6H), 6.74 (d, $J = 16.0$ Hz, 1H), 6.39 (dt, $J = 16.0, 5.6$ Hz, 1H), 4.88 (dd, $J = 5.6, 1.4$ Hz, 2H), 4.04 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 167.9, 153.9, 136.2, 132.9, 130.8, 130.6, 129.9, 129.6, 129.5, 128.6, 127.9, 126.5, 125.6, 123.9, 118.4, 117.9, 115.8, 70.3, 52.5; HRMS (ESI+) m/z calcd. for $\text{C}_{21}\text{H}_{17}\text{BrNaO}_3$: 419.0253; found: 419.0252.

Methyl 3-bromo-2-(cinnamyloxy)-1-naphthoate (**1o**):




1o was isolated by FC on silica gel using pentane/EtOAc 30:1; 78% yield; colorless liquid; IR (neat) 2947, 1731, 1278, 1224, 748 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.18 (s, 1H), 7.76 (d, $J = 9.4$ Hz, 1H), 7.57 – 7.54 (m, 1H), 7.50 – 7.26 (m, 7H), 6.76 (d, $J = 15.9$ Hz, 1H), 6.50 (dt, $J = 15.9, 6.2$ Hz, 1H), 4.81 (dd, $J = 6.2, 1.3$ Hz, 2H), 4.02 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 167.4, 150.7, 136.4, 134.4, 133.7, 131.3, 129.9, 128.6, 127.9, 127.7, 127.2, 126.7, 126.4, 125.7, 124.5, 124.2, 116.8, 75.9, 52.8; HRMS (ESI+) m/z calcd. for $\text{C}_{21}\text{H}_{17}\text{BrNaO}_3$: 419.0253; found: 419.0250.

Benzyl 2-(cinnamyloxy)-1-naphthoate (**1p**):



1p was isolated by FC on silica gel using pentane/EtOAc 30:1; 83% yield; white solid; m.p. = 62.3 $^{\circ}\text{C}$; IR (film) 3025, 1727, 1510, 1281, 1226, 747 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.87 (d, $J = 9.1$ Hz, 1H), 7.79 – 7.42 (m, 2H), 7.49 – 7.46 (m, 3H), 7.38 – 7.25 (m, 10H), 6.70 (d, $J = 16.0$ Hz, 1H), 6.34 (dt, $J = 15.9, 5.7$ Hz, 1H), 5.51 (s, 2H), 4.85 (d, $J = 5.7$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 167.9, 153.6, 136.3, 135.8, 133.0, 131.6, 131.0, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.6, 126.6, 124.2, 124.1, 123.8, 118.2, 114.7, 70.3, 67.1; HRMS (ESI+) m/z calcd. for $\text{C}_{27}\text{H}_{22}\text{NaO}_3$: 417.1461; found: 417.1454.


Methyl 2-(cinnamyloxy)-6-(*p*-tolyl)-1-naphthoate (**1q**):



1q was isolated by FC on silica gel using pentane/EtOAc 30:1; 83% yield; white solid; IR (film) 1722, 1499, 1290, 1248, 813 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.97 (d, $J = 1.6$ Hz, 1H), 7.93 (d, $J = 9.0$ Hz, 1H), 7.83 (d, $J = 8.8$ Hz, 1H), 7.77 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.60 – 7.59 (m, 2H), 7.42 – 7.40 (m, 2H), 7.37 – 7.31 (m, 3H), 7.30 – 7.26 (m, 3H), 6.76 (d, $J = 16.0$ Hz, 1H), 6.42 (dt, $J = 16.0, 5.5$ Hz, 1H), 4.90 (dd, $J = 5.5, 1.4$ Hz, 3H), 4.06 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 153.6, 137.6, 137.1, 136.9, 136.3, 132.7, 131.8, 130.0, 129.6, 129.0, 128.5, 127.9, 127.2, 127.0, 126.5, 125.4, 124.4, 124.2, 118.2, 115.2, 70.3, 52.4, 21.1; HRMS (ESI+) m/z calcd. for $\text{C}_{28}\text{H}_{24}\text{NaO}_3$: 431.1618; found: 431.1612.

Methyl 2-(cinnamyloxy)-6-(phenylethynyl)-1-naphthoate (**1r**):


1r was isolated by FC on silica gel using pentane/EtOAc 30:1; 83% yield; white solid; m.p. = 126.6 $^{\circ}\text{C}$; IR (film) 2951, 1728, 1597, 1282, 1250, 756 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.00 (s,



1H), 7.86 (d, $J = 9.1$ Hz, 1H), 7.74 (d, $J = 8.8$ Hz, 1H), 7.61 – 7.56 (m, 3H), 7.41 – 7.26 (m, 9H), 6.75 (d, $J = 16.0$ Hz, 1H), 6.41 (dt, $J = 16.0, 5.6$ Hz, 1H), 4.90 (dd, $J = 5.5, 1.2$ Hz, 2H), 4.05 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.1, 154.3, 136.2, 132.9,

131.6, 131.5, 130.4, 130.1, 128.6, 128.3, 127.9, 126.5, 124.0, 123.2, 119.0, 118.3, 115.3, 89.8, 89.4, 70.2, 52.5; HRMS (ESI+) m/z calcd. for $\text{C}_{29}\text{H}_{22}\text{NaO}_3$: 441.1461; found: 441.1458.


Methyl 2-[(3,4-dimethoxybenzyl)oxy]-1-naphthoate (1s):



1s was isolated by FC on silica gel using pentane/EtOAc 15:1; 78% yield; yellow viscous liquid; IR (neat) 2950, 2835, 1727, 1514, 1238, 1138, 1028, 811 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.83 (d, $J = 9.1$

Hz, 1H), 7.76 (t, $J = 8.4$ Hz, 2H), 7.49 (t, $J = 8.1$ Hz, 1H), 7.36 (t, $J = 7.5$ Hz, 1H), 7.27 (d, $J = 9.1$ Hz, 1H), 7.02 (d, $J = 1.7$ Hz, 1H), 6.95 (d, $J = 8.1$ Hz, 1H), 6.83 (d, $J = 8.1$ Hz, 1H), 5.19 (s, 2H), 4.00 (s, 3H), 3.89 (s, 3H), 3.86 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 153.5, 149.0, 148.7, 131.4, 130.9, 129.2, 128.7, 128.0, 127.5, 124.3, 123.7, 119.6, 118.5, 114.9, 110.8, 110.4, 71.4, 55.8, 55.7, 52.3; HRMS (ESI+) m/z calcd. for $\text{C}_{21}\text{H}_{20}\text{NaO}_5$: 375.1203; found: 375.1199.


Methyl 2-[(4-methoxybenzyl)oxy]-1-naphthoate (1t):



1t was isolated by FC on silica gel using pentane/EtOAc 30:1; 81% yield; yellow solid; m.p. = 79.2 $^{\circ}\text{C}$; IR (film) 2951, 1728, 1513, 1284, 1245, 812 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.80 (d, $J = 9.1$ Hz,

1H), 7.76 – 7.74 (m, 2H), 7.47 (t, $J = 7.6$ Hz, 1H), 7.36 – 7.32 (m, 3H), 7.24 (d, $J = 9.1$ Hz, 1H), 6.88 (d, $J = 8.6$ Hz, 2H), 5.15 (s, 2H), 3.98 (s, 3H), 3.76 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 159.3, 153.6, 131.4, 130.9, 128.7, 128.6, 128.0, 127.5, 124.2, 123.8, 118.5, 115.0, 113.8, 71.3, 55.2, 52.3; HRMS (ESI+) m/z calcd. for $\text{C}_{20}\text{H}_{18}\text{NaO}_4$: 345.1097; found: 345.1095.

Methyl 2-(benzo[d][1,3]dioxol-5-ylmethoxy)-1-naphthoate (1u):




1u was isolated by FC on silica gel using pentane/EtOAc 20:1; 85% yield; yellow viscous liquid; IR (neat) 2950, 1727, 1504, 1445, 1244, 1038, 810 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.82 (d, $J = 9.0$ Hz, 1H),


7.76 (d, $J = 8.6$ Hz, 2H), 7.48 (t, $J = 7.6$ Hz, 1H), 7.37 (d, $J = 7.6$ Hz, 1H), 7.24 (d, $J = 9.0$ Hz, 1H), 6.93 (s, 1H), 6.86 (d, $J = 7.9$ Hz, 1H), 6.77 (d, $J = 7.9$ Hz, 1H), 5.93 (s, 2H), 5.12 (s, 2H), 4.01 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 153.4, 147.8, 147.3, 131.5, 130.9, 130.5, 128.7, 128.0, 127.6, 124.3, 123.8, 120.8, 118.5, 114.9, 108.1, 107.9, 101.0, 71.5, 52.3; HRMS (ESI+) m/z calcd. for $\text{C}_{20}\text{H}_{16}\text{NaO}_5$: 359.0890; found: 359.0884.

Methyl (*E*)-2-[(2-methyl-3-phenylallyl)oxy]-1-naphthoate (1v):

1v was isolated by FC on silica gel using pentane/EtOAc 30:1; 83% yield; white solid; m.p. = 87.7 $^{\circ}\text{C}$; IR (film) 2949, 1729, 1510, 1284, 1234, 1136, 748 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3)



δ 7.89 (d, $J = 9.0$ Hz, 1H), 7.80 (d, $J = 8.2$ Hz, 1H), 7.77 (d, $J = 8.5$ Hz, 1H), 7.52 – 7.49 (m, 1H), 7.40 – 7.28 (m, 6H), 7.25 – 7.22 (m, 1H), 6.66 (s, 1H), 4.75 (s, 2H), 4.04 (s, 3H), 1.98 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.4, 153.6, 137.1, 133.4, 131.5, 131.0, 128.9, 128.6, 128.1, 128.0, 127.5, 127.5, 126.6, 124.2, 123.8, 118.2, 114.6, 75.2, 52.3, 15.12; HRMS (ESI+) m/z calcd. for $\text{C}_{22}\text{H}_{20}\text{NaO}_3$: 335.1305; found: 335.1300.



1-allylnaphthalen-2-ol³ and 1-phenylnaphthalen-2-ol⁴ were synthesized according to the literature. 3a and 3b were synthesized based on the literature⁵ with a little modification, the modified procedure was shown as below.


To a solution of MOMO protected 1-allylnaphthalen-2-ol or 1-phenylnaphthalen-2-ol (5.00 mmol) in Et_2O (20.0 mL) was added $n\text{-BuLi}$ (6.25 mL, 10.0 mmol, 1.6M in hexane) at 0 °C. The reaction mixture was allowed to room temperature. After stirring for 1 h at room temperature, the reaction was quenched by dry ice (ca. 1 g) slowly, and then solvents were removed in vacuo. To the residue in Acetone (50.0 mL) were added iodomethane (0.778 mL, 10.0 mmol) and Cs_2CO_3 (4.4 g, 12.5 mmol) at room temperature. After stirring for 2 h at 40 °C, the resulting mixture was poured into water and the aqueous layers were extracted with EtOAc (twice). The combined organic layers were washed with brine and dried over anhydrous MgSO_4 , then the solvents were removed in vacuo. The residue was purified by flash column chromatography on silica gel to give the corresponding ester.

To a solution of the corresponding ester intermediate in MeOH (0.2 M) was added conc. HCl aq. (a few drops). The reaction mixture was warmed to 50 °C. After stirring for 2 h, water was added to the resulting mixture, and the aqueous layers were extracted with EtOAc . The combined organic layers were washed with brine and dried over anhydrous MgSO_4 , then the solvents were removed

in vacuo. The residue was directly used in next step without further purification.


Then **3a** and **3b** could be synthesized by using the same procedure for the synthesis of methyl 2-allyloxy- and 2-Benzyloxy-1-naphthoates as we mentioned at the beginning of part 3.

Methyl (*E*)-4-phenyl-3-((3-(thiophen-3-yl)allyl)oxy)-2-naphthoate (3a**):**



3a was isolated as yellow solid by FC on silica gel using pentane/EtOAc 30:1; 64% yield; yellow solid; m.p. = 75.3 °C; IR (neat) 2948, 1728, 1446, 1301, 1211, 965, 754 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.40 (s, 1H), 7.90 (dd, *J* = 6.5, 2.8 Hz, 1H), 7.58 – 7.43 (m, 8H), 7.21 (dd, *J* = 4.9, 3.0 Hz, 1H), 7.07 (d, *J* = 5.0 Hz, 1H), 7.03 (d, *J* = 2.6 Hz, 1H), 6.27 (d, *J* = 15.8 Hz, 1H), 5.79 (dt, *J* = 15.7, 6.4 Hz, 1H), 4.29 (d, *J* = 6.4 Hz, 2H), 3.97 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 166.9, 151.8, 139.2, 135.6, 135.2, 133.1, 132.2, 131.1, 129.7, 128.9, 128.2, 128.1, 127.5, 127.2, 125.8, 125.5, 125.2, 125.1, 124.7, 122.4, 75.3, 52.4.; HRMS (ESI+) *m/z* calcd. for C₂₅H₂₀NaO₃S: 423.1025; found: 423.1017.

Methyl (*E*)-4-allyl-3-((3-(thiophen-3-yl)allyl)oxy)-2-naphthoate (3b**):**



3b was isolated as yellow viscous liquid by FC on silica gel using pentane/EtOAc 30:1; 42% yield; yellow viscous liquid; IR (neat) 2948, 1726, 1446, 1219, 1159, 964, 752 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.32 (s, 1H), 7.96 (d, *J* = 8.5 Hz, 1H), 7.88 (d, *J* = 8.1 Hz, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.46 (t, *J* = 7.5 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.20 (s, 1H), 6.74 (d, *J* = 15.8 Hz, 1H), 6.36 (dt, *J* = 15.8, 6.1 Hz, 1H), 6.10 (ddd, *J* = 22.6, 10.6, 5.6 Hz, 1H), 5.07 (d, *J* = 10.2 Hz, 1H), 4.97 (d, *J* = 17.2 Hz, 1H), 4.62 (d, *J* = 6.1 Hz, 2H), 3.96 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 167.0, 152.4, 139.3, 136.7, 135.0, 131.9, 129.9, 129.5, 128.6, 128.2, 127.2, 126.0, 125.3, 125.1, 124.8, 124.6, 124.5, 122.7, 116.0, 75.9, 52.4, 29.8; HRMS (ESI+) *m/z* calcd. for C₂₂H₂₀NaO₃S: 387.1025; found: 387.1029.


4. General Procedure for Catalytic Asymmetric [1,3] Rearrangement of Methyl 2-Allyloxy- and 2-Benzyloxy-1-naphthoates

L8 (0.0165 mmol) and Cu(OTf)₂ (0.015 mmol) were stirred in 0.4 mL of DCM at room temperature for 0.5 h, then the reaction system was cooled to specific temperature. Naphthyl ethers **1** (0.15 mmol) was dissolved in 0.35 mL DCM and added to the system. The mixture was stirred at the same temperature until reaction completed. Then the solvent was removed, and the residue was purified by flash chromatography on silica gel (products **2s**, **2t**, **2u**, **4a** and **4b** were purified using diol silica gel) to give the product **2**, which was then directly analyzed by HPLC to determine the enantiomeric excess.


5. Prospect for Appropriate Substrate and Optimization of the Reaction Conditions

As shown in Scheme S1, compounds **1** are appropriate substrates for the [1,3] rearrangement. 1-Methoxycarbonyl moiety of **1** was important for chelation with $\text{Cu}(\text{OTf})_2$. 3-Aryl substituent on the allyl moiety of **1** was also important for [1,3] rearrangement because of the stability of the tight ion-pair transition state. Secondary allylic ether **1F** was decomposed to 2-hydroxy-1-naphthoate without giving **2F** under the same conditions.

Scheme S1: Prospect for appropriate substrates^a




^aAll reactions were carried out with 0.15 mmol of **1** in 0.75 mL of DCM.

Table S1: Ligand screening^a


^aAll reactions were carried out with 0.15 mmol of **1a** in 0.75 mL of DCM. ^bBased on NMR. ^cDetermined by HPLC analysis. ^dThe reaction was carried out at 30 °C.

As shown in Table S2, dichloromethane was the best solvent. 1,2-Dichloroethane was also available. However, Et₂O reduced the reactivity and the ee value. More polar solvents like ethers, esters and methanol were less effective because Lewis acidity of the catalyst was seriously decreased in polar solvents. In addition, the rearrangement did not occur in less polar toluene even at 30 °C. Judging from these experimental results, polarity of halogenated solvents may be effective to stabilize the tight ion pair transition state. Moreover, available solvents are also limited due to the solubility of ligands and substrates.

It was noted that this rearrangement more cleanly occurred in the presence of $\text{Cu}(\text{OTf})_2 \cdot \mathbf{L11}$ or $\text{Cu}(\text{OTf})_2 \cdot \mathbf{L8}$, although $\text{Cu}(\text{OTf})_2$ was active for this rearrangement (cf. Scheme S1). Moreover, **L11** was inferior to **L8** with regard to the enantioselectivity, regioselectivity (**2a**:**2a'**) and catalytic activity, probably due to some undesired steric hindrance of $\text{Cu}(\text{OTf})_2 \cdot \mathbf{L11}$ (cf. Table 1).

Table S2: Solvent effect^a


solvent	temp [°C]	conv. [%] ^b	2a : 2a' ^b	Ee [%] ^c	Comments
toluene	30	0	–	–	
CH_2Cl_2	30	100	66 : 34	58	
CH_2Cl_2	-20	100	77 : 23	83	
$\text{ClCH}_2\text{CH}_2\text{Cl}$	-20	93	77 : 23	83	
Et_2O	30	34	59 : 41	35	L11 was not dissolved.
THF	30	0	–	–	
EtOAc	30	0	–	–	
MeCN	30	0	–	–	
MeOH	30	0	–	–	1a was not dissolved.



^aAll reactions were carried out with 0.10 mmol of **1a** in 0.5 mL of solvent. ^bBased on NMR. ^cDetermined by HPLC analysis.


6. Spectral Characterization Data for the Products

Methyl (*S*)-1-cinnamyl-2-oxo-1,2-dihydronaphthalene-1-carboxylate (**2a**):



Yield (90%); colorless viscous liquid; IR (neat) 3026, 2950, 1742, 1663, 1222, 746 cm^{-1} ; $[\alpha]_{\text{D}}^{26} = +111.9$ (*c* 1.50, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.46 – 7.43 (m, 2H), 7.38 – 7.34 (m, 3H), 7.20 – 7.17 (m, 2H), 7.16 – 7.14 (m, 1H), 7.09 – 7.07 (m, 2H), 6.20 – 6.17 (m, 2H), 5.68 – 5.62 (m, 1H), 3.65 (s, 3H), 3.28 (ddd, *J* = 13.6, 8.1, 1.0 Hz, 1H), 3.14 (ddd, *J* = 13.6, 7.0, 1.3 Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 197.4, 170.9, 146.0, 139.2, 136.9, 134.0, 130.4, 129.7, 129.5, 128.2, 128.1, 127.2, 126.9, 126.0, 125.2, 122.1, 62.6, 52.9, 43.9; HRMS (ESI+) *m/z* calcd. for $\text{C}_{21}\text{H}_{18}\text{NaO}_3$: 341.1148; found: 341.1154; The product was analyzed by HPLC to determine the enantiomeric excess: 91% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); t_{r} = 6.83 and 8.65 min.


Methyl (*S,E*)-2-oxo-1-[3-(*o*-tolyl)allyl]-1,2-dihydronaphthalene-1-carboxylate (**2b**):



Yield (90%); colorless viscous liquid; $[\alpha]_{\text{D}}^{28} = +76.2$ (*c* 0.84, CHCl_3); IR (neat) 3023, 2952, 1742, 1663, 1222, 967, 750 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.46-7.43 (m, 2H), 7.39 – 7.32 (m, 3H), 7.05 – 7.00 (d, *J* = 25.3 Hz, 4H), 6.34 (d, *J* = 15.6 Hz, 1H), 6.19 (d, *J* = 9.9 Hz, 1H), 5.51 (dt, *J* = 15.4, 7.6 Hz, 1H), 3.64 (s, 3H), 3.32 (dd, *J* = 13.5, 7.8 Hz, 1H), 3.17 (dd, *J* = 13.5, 7.4 Hz, 1H), 2.06 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 197.4, 170.9, 146.1, 139.3, 136.3, 135.1, 132.5, 130.4, 129.9, 129.7, 129.6, 128.1, 127.2, 127.0, 125.8, 125.6, 125.3, 123.7, 62.8, 52.9, 44.2, 19.5; HRMS

(ESI+) m/z calcd. for $C_{22}H_{20}NaO_3$: 355.1305; found: 355.1306; The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 272 nm); t_r = 6.24 and 6.74 min.


Methyl (*S,E*)-2-oxo-1-[3-(*m*-tolyl)allyl]-1,2-dihydronaphthalene-1-carboxylate (2c**):**



Yield (91%); colorless viscous liquid; $[\alpha]_D^{28} = +93.8$ (c 0.83, $CHCl_3$); IR (neat) 3024, 2951, 1743, 1663, 1223, 764 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.46 – 7.42 (m, 2H), 7.38 – 7.33 (m, 3H), 7.09 – 7.06 (m, 1H), 6.96 (d, J = 7.5 Hz, 1H), 6.90 – 6.98 (m, 2H), 6.19 (d, J = 9.9 Hz, 1H), 6.14 (d, J = 15.7

Hz, 1H), 5.64 (dt, J = 15.4, 7.6 Hz, 1H), 3.64 (s, 3H), 3.28 (dd, J = 13.6, 8.1 Hz, 1H), 3.13 (dd, J = 13.6, 7.1 Hz, 1H), 2.25 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 197.4, 171.0, 146.0, 139.3, 137.8, 136.9, 134.2, 130.4, 129.7, 129.6, 128.2, 128.1, 128.0, 127.0, 126.9, 125.3, 123.1, 122.0, 62.8, 52.9, 44.0, 21.2; HRMS (ESI+) m/z calcd. for $C_{22}H_{20}NaO_3$: 355.1305; found: 355.1301. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); t_r = 6.56 and 8.02 min.


Methyl (*S,E*)-2-oxo-1-[3-(*p*-tolyl)allyl]-1,2-dihydronaphthalene-1-carboxylate (2d**):**



Yield (87%); colorless viscous liquid; $[\alpha]_D^{28} = +93.1$ (c 0.85, $CHCl_3$); IR (neat) 3034, 2951, 1742, 1664, 1223, 764 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.45 – 7.41 (m, 2H), 7.36 – 7.31 (m, 3H), 7.00 – 6.96 (m, 4H), 6.17 (d, J = 9.9 Hz, 1H), 6.14 (d, J = 15.8 Hz, 1H), 5.60 (dt, J = 15.5, 7.6

Hz, 1H), 3.63 (s, 3H), 3.27 (dd, J = 13.5, 8.1 Hz, 1H), 3.13 (dd, J = 13.5, 7.0 Hz, 1H), 2.25 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 197.5, 171.0, 146.0, 139.3, 137.0, 134.2, 133.9, 130.3, 129.7, 129.6, 129.0, 128.0, 126.9, 125.9, 125.3, 121.1, 62.8, 52.9, 44.0, 21.0; HRMS (ESI+) m/z calcd. for $C_{22}H_{20}NaO_3$: 355.1305; found: 355.1306. The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); t_r = 6.67 and 10.29 min.

Methyl (*S,E*)-1-[3-(4-bromophenyl)allyl]-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2e**):**




Yield (76%); yellow viscous liquid; $[\alpha]_D^{29} = +98.1$ (c 0.84, $CHCl_3$); IR (neat) 3026, 2951, 1742, 1663, 1487, 1223, 761 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.46 – 7.43 (m, 2H), 7.38 – 7.33 (m, 3H), 7.30 – 7.29 (m, 2H), 6.94 – 6.93 (m, 2H), 6.18 (d, J = 9.9 Hz, 1H), 6.11 (d, J = 15.7

Hz, 1H), 5.69 – 5.62 (m, 1H), 3.64 (s, 3H), 1H 3.27 (ddd, J = 13.6, 8.1, 0.9 Hz, 1H), 3.11 (ddd, J = 13.6, 7.0, 1.2 Hz, 1H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 197.2, 170.8, 146.0, 139.1, 135.8, 132.9, 131.4, 130.4, 129.8, 129.5, 128.2, 127.6, 126.9, 125.2, 123.2, 121.0, 62.6, 52.9, 43.8; HRMS (ESI+) m/z calcd. for $C_{21}H_{17}BrNaO_3$: 419.0253; found: 419.0251. The product was analyzed by HPLC to


determine the enantiomeric excess: 91% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 8.05$ and 11.36 min.

Methyl (*S,E*)-1-[3-(4-chlorophenyl)allyl]-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2f):




Yield (78%); colorless viscous liquid; $[\alpha]_D^{29} = +113.7$ (*c* 0.83, CHCl₃); IR (neat) 3038, 2952, 1742, 1663, 1224, 761 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.46 – 7.43 (m, 2H), 7.38 – 7.34 (m, 3H), 7.15 – 7.13 (m, 2H), 7.01 – 6.99 (m, 2H), 6.18 (d, *J* = 9.9 Hz, 1H), 6.13 (d, *J* = 15.8 Hz, 1H), 5.67-5.61 (m, 1H), 3.64 (s, 3H), 3.27 (ddd, *J* = 13.6, 8.1, 1.0 Hz, 1H), 3.11 (ddd, *J* = 13.6, 7.0, 1.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 197.3, 170.8, 146.0, 139.2, 135.4, 132.9, 130.4, 129.8, 129.5, 128.5, 128.2, 127.2, 126.9, 125.3, 123.1, 62.7, 52.9, 43.8; HRMS (ESI+) *m/z* calcd. for C₂₁H₁₇ClNaO₃: 375.0758; found: 375.0760. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 7.78$ and 10.73 min.

Methyl (*S,E*)-1-[3-(naphthalen-1-yl)allyl]-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2g):



Yield (95%); colorless viscous liquid; $[\alpha]_D^{30} = +40.5$ (*c* 0.84, CHCl₃); IR (neat) 3038, 2951, 1742, 1662, 1224, 761 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.77 – 7.75 (m, 1H), 7.67 (d, *J* = 8.2 Hz, 1H), 7.63 (d, *J* = 8.2 Hz, 1H), 7.50 – 7.47 (m, 1H), 7.44 – 7.29 (m, 7H), 7.20 (d, *J* = 7.1 Hz, 1H), 6.85 (d, *J* = 15.5 Hz, 1H), 6.21 (d, *J* = 9.9 Hz, 1H), 5.66 (dt, *J* = 15.3, 7.6 Hz, 1H), 3.67 (s, 3H), 3.42 (dd, *J* = 13.4, 7.8 Hz, 1H), 3.26 (dd, *J* = 13.4, 7.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 197.5, 170.9, 146.1, 139.4, 135.0, 133.3, 132.1, 130.9, 130.5, 129.8, 129.7, 128.2, 128.1, 127.6, 127.0, 125.8, 125.6, 125.5, 125.4, 125.3, 123.9, 123.7, 62.8, 53.0, 44.3; HRMS (ESI+) *m/z* calcd. for C₂₅H₂₀NaO₃: 391.1305; found: 391.1310. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 7.60$ and 8.35 min.


Methyl (*S,E*)-1-[3-(naphthalen-2-yl)allyl]-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2h):



Yield (86%); colorless viscous liquid; $[\alpha]_D^{20} = +120.0$ (*c* 0.85, CHCl₃); IR (neat) 3022, 2951, 1742, 1662, 1224, 757 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.71 – 7.68 (m, 2H), 7.63 (d, *J* = 8.6 Hz, 1H), 7.46 – 7.31 (m, 8H), 7.26 (dd, *J* = 8.6, 1.5 Hz, 1H), 6.33 (d, *J* = 15.7 Hz, 1H), 6.19 (d, *J* = 9.9 Hz, 1H), 5.79 (dt, *J* = 15.4, 7.6 Hz, 1H), 3.64 (s, 3H), 3.34 (dd, *J* = 13.6, 8.1 Hz, 1H), 3.18 (dd, *J* = 13.6, 7.1 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 197.4, 171.0, 146.0, 139.3, 134.4, 134.2, 133.4, 132.7, 130.4, 129.8, 129.6, 128.1, 127.9, 127.8, 127.5, 127.0, 126.1, 125.8, 125.7, 125.3, 123.4, 122.7, 62.8, 52.9, 44.11; HRMS (ESI+) *m/z* calcd. for C₂₅H₂₀NaO₃: 391.1305; found:


391.1303. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 8.77$ and 13.43 min.

Methyl (*S,E*)-1-[3-(furan-3-yl)allyl]-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2i**):**




Yield (63%); colorless viscous liquid; $[\alpha]_D^{27} = +59.4$ (c 0.95, CHCl_3); IR (neat) 3026, 1742, 1661, 1225, 759 cm^{-1} ; $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.46 – 7.42 (m, 2H), 7.38 – 7.34 (m, 3H), 7.23 – 7.19 (m, 2H), 6.22 (d, $J = 1.6$ Hz, 1H), 6.19 (d, $J = 9.9$ Hz, 1H), 6.03 (d, $J = 15.7$ Hz, 1H), 5.40 – 5.34 (m, 1H), 3.64 (s, 3H), 3.23 (ddd, $J = 13.6, 8.2, 0.9$ Hz, 1H), 3.08 (ddd, $J = 13.6, 7.0, 1.2$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 197.4, 171.0, 146.0, 143.1, 140.0, 139.3, 130.4, 129.7, 129.6, 128.1, 127.0, 125.4, 123.8, 121.8, 107.4, 62.8, 52.9, 43.8; HRMS (ESI+) m/z calcd. for $\text{C}_{19}\text{H}_{16}\text{NaO}_4$: 331.0941; found: 331.0950. The product was analyzed by HPLC to determine the enantiomeric excess: 96% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 7.69$ and 10.62 min.

Methyl (*S,E*)-2-oxo-1-[3-(thiophen-3-yl)allyl]-1,2-dihydronaphthalene-1-carboxylate (2j**):**



Yield (85%); colorless liquid; $[\alpha]_D^{27} = +107.1$ (c 1.14, CHCl_3); IR (neat) 2959, 1741, 1661, 1224, 765 cm^{-1} ; $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.45 – 7.42 (m, 2H), 7.38 – 7.34 (m, 3H), 7.13 – 7.11 (m, 1H), 6.90 – 6.89 (m, 2H), 6.20 – 6.17 (m, 2H), 5.53–5.47 (m, 1H), 3.63 (s, 3H), 3.25 (dd, $J = 13.6, 8.2$ Hz, 1H), 3.10 (ddd, $J = 13.6, 7.0, 1.1$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 197.4, 170.9, 146.0, 139.6, 139.3, 130.4, 129.7, 129.6, 128.3, 128.1, 126.9, 125.6, 125.3, 124.9, 122.1, 121.5, 62.7, 52.9, 43.8; HRMS (ESI+) m/z calcd. for $\text{C}_{19}\text{H}_{16}\text{NaO}_3\text{S}$: 347.0712; found: 347.0720. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 8.48$ and 13.16 min.


Methyl (*S,E*)-2-oxo-1-[3-phenylbut-2-en-1-yl]-1,2-dihydronaphthalene-1-carboxylate (2k**):**



Yield (92%); colorless viscous liquid; $[\alpha]_D^{28} = +81.0$ (c 0.84, CHCl_3); IR (neat) 3022, 2951, 1743, 1663, 1224, 760 cm^{-1} ; $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.48 (d, $J = 9.9$ Hz, 1H), 7.42 – 7.39 (m, 1H), 7.36 – 7.34 (m, 3H), 7.21 – 7.13 (m, 3H), 7.08 – 7.06 (m, 2H), 6.22 (d, $J = 9.9$ Hz, 1H), 5.25 – 5.20 (m, 1H), 3.65 (s, 3H), 3.34 (dd, $J = 14.2, 8.2$ Hz, 1H), 3.14 (dd, $J = 14.2, 7.2$ Hz, 1H), 1.77 (s, 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 197.6, 171.2, 146.0, 143.6, 139.5, 138.9, 130.3, 129.7, 128.1, 128.0, 127.7, 127.1, 126.7, 125.7, 125.3, 119.9, 62.6, 52.9, 39.7, 16.0; HRMS (ESI+) m/z calcd. for $\text{C}_{22}\text{H}_{20}\text{NaO}_3$: 355.1310; found: 355.12306. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 6.67$ and


9.22 min.

Methyl (S)-1-[3,3-bis(4-chlorophenyl)allyl]-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2l):




Yield (89%); white solid; m.p. = 99.5 °C; $[\alpha]_D^{24} = +109.16$ (*c* 0.85, CHCl₃); IR (neat) 3027, 2952, 1743, 1664, 1490, 1224, 1092, 830, 759 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.55 (d, *J* = 9.9 Hz, 1H), 7.40–7.30 (m, 3H), 7.27 – 7.25 (m, 2H), 7.13 – 7.12 (m, 2H), 7.06 (d, *J* = 7.5 Hz, 1H), 6.82 (d, *J* = 8.4 Hz, 2H), 6.73 (d, *J* = 8.2 Hz, 2H), 6.27 (d, *J* = 9.9 Hz, 1H), 5.65 (t, *J* = 7.6 Hz, 1H), 3.60 (s, 3H), 3.20 (dd, *J* = 14.3, 7.0 Hz, 1H), 3.03 (dd, *J* = 14.3, 8.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 197.1, 170.8, 146.2, 143.0, 140.2, 139.1, 137.0, 133.2, 133.2, 131.0, 130.6, 129.7, 129.4, 128.5, 128.4, 128.2, 128.2, 127.1, 125.2, 122.5, 62.5, 53.0, 40.2; HRMS (ESI+) *m/z* calcd. for C₂₇H₂₀Cl₂NaO₃: 485.0682; found: 485.0678. The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralpak AD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); *t_r* = 8.02 and 10.86 min.

Methyl (S)-1-(3-methylbut-2-en-1-yl)-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2m):



Yield (58%); colorless liquid; $[\alpha]_D^{29} = -3.8$ (*c* 0.83, CHCl₃); IR (neat) 2952, 2913, 1742, 1664, 1227, 828, 762 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.47 (d, *J* = 9.9 Hz, 1H), 7.41 – 7.38 (m, 1H), 7.35 – 7.34 (m, 2H), 7.30 (d, *J* = 7.6 Hz, 1H), 6.19 (d, *J* = 9.9 Hz, 1H), 4.64 (tdd, *J* = 7.0, 2.8, 1.4 Hz, 1H), 3.62 (s, 3H), 3.14 (dd, *J* = 14.1, 8.1 Hz, 1H), 2.91 (dd, *J* = 14.1, 7.0 Hz, 1H), 1.47 (s, 3H), 1.35 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 197.8, 171.3, 145.8, 139.7, 135.9, 130.2, 129.7, 129.5, 127.8, 127.0, 125.4, 116.2, 62.6, 52.8, 39.2, 25.6, 17.7; HRMS (ESI+) *m/z* calcd. for C₁₇H₁₈NaO₃: 293.1148; found: 293.1152. The product was analyzed by HPLC to determine the enantiomeric excess: 68% ee (Chiralpak AS-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 290 nm); *t_r* = 5.63 and 6.08 min.


Methyl (S)-6-bromo-1-cinnamyl-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2n):




Yield (95%); yellow viscous liquid; $[\alpha]_D^{26} = +115.7$ (*c* 0.84, CHCl₃); IR (neat) 3027, 2950, 1743, 1667, 1224, 748 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.56 (dd, *J* = 8.3, 1.8 Hz, 1H), 7.49 (d, *J* = 1.6 Hz, 1H), 7.36 (d, *J* = 9.9 Hz, 1H), 7.25 – 7.14 (m, 4H), 7.11 – 7.09 (m, 2H), 6.23 – 6.19 (m, 2H), 5.64 (dt, *J* = 15.4, 7.6 Hz, 1H), 3.64 (s, 3H), 3.28 (dd, *J* = 13.6, 8.2 Hz, 1H), 3.11 (dd, *J* = 13.6, 7.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 196.7, 170.4, 144.3, 137.8, 136.7, 134.4, 133.1, 132.2, 131.4, 128.6, 128.3, 127.4, 126.4, 126.1, 121.9, 121.7, 62.4, 53.1, 43.6; HRMS (ESI+) *m/z* calcd. for C₂₁H₁₇BrNaO₃: 419.0253; found: 419.0251. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); *t_r* = 7.32 and 9.04

min.


Methyl (S)-3-bromo-1-cinnamyl-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2o):

 Yield (95%); yellow viscous liquid; $[\alpha]_D^{27} = +0.9$ (*c* 0.84, CHCl₃); IR (neat) 3027, 2952, 1745, 1675, 1229, 748 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.87 (s, 1H), 7.48 – 7.45 (m, 1H), 7.38 – 7.35 (m, 2H), 7.29 (d, *J* = 7.4 Hz, 1H), 7.20 – 7.12 (m, 3H), 7.09–7.07 (m, 2H), 6.19 (d, *J* = 15.7 Hz, 1H), 5.60 (dt, *J* = 15.5, 7.6 Hz, 1H), 3.63 (s, 3H), 3.31 (dd, *J* = 13.6, 8.1 Hz, 1H), 3.15 (ddd, *J* = 13.5, 7.1, 0.7 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 190.4, 170.2, 147.3, 138.6, 136.8, 134.7, 130.7, 130.0, 129.3, 128.4, 128.3, 127.4, 126.9, 126.1, 121.5, 121.4, 64.1, 53.1, 44.3; HRMS (ESI+) *m/z* calcd. for C₂₁H₁₇BrNaO₃: 419.0253; found: 419.0253. The product was analyzed by HPLC to determine the enantiomeric excess: 81% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); *t*_r = 7.91 and 16.81 min.

Benzyl (S)-1-cinnamyl-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2p):


 Yield (82%); colorless viscous liquid; $[\alpha]_D^{28} = +32.5$ (*c* 0.85, CHCl₃); IR (neat) 3029, 1742, 1663, 1214, 744 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.43 (d, *J* = 9.9 Hz, 1H), 7.40 – 7.32 (m, 3H), 7.29 – 7.24 (m, 4H), 7.20 – 7.12 (m, 3H), 7.08 – 7.07 (m, 4H), 6.20 – 6.17 (m, 2H), 5.69 – 5.63 (m, 1H), 5.14 – 5.08 (m, 2H), 3.31 (dd, *J* = 13.6, 8.1 Hz, 1H), 3.14 (dd, *J* = 13.7, 7.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 197.3, 170.1, 146.0, 139.1, 137.0, 135.4, 134.1, 130.3, 129.7, 129.6, 128.3, 128.1, 127.9, 127.4, 127.2, 127.0, 126.1, 125.3, 122.3, 67.1, 62.9, 43.7; HRMS (ESI+) *m/z* calcd. for C₂₇H₂₂NaO₃: 417.1461; found: 417.1462. The product was analyzed by HPLC to determine the enantiomeric excess: 89% ee (Chiralpak AD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); *t*_r = 13.4 and 15.15 min.

Methyl (S)-1-cinnamyl-2-oxo-6-(*p*-tolyl)-1,2-dihydronaphthalene-1-carboxylate (2q):

 Yield (95%); colorless viscous liquid; $[\alpha]_D^{31} = +120.4$ (*c* 0.84, CHCl₃); IR (neat) 3034, 2951, 1742, 1665, 1234, 815, 751 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.65 (dd, *J* = 8.1, 1.8 Hz, 1H), 7.54 – 7.49 (m, 4H), 7.42 (d, *J* = 8.1 Hz, 1H), 7.28 – 7.27 (m, 2H), 7.19 – 7.09 (m, 5H), 6.25 – 6.21 (m, 2H), 5.70 (dt, *J* = 15.3, 7.5 Hz, 1H), 3.66 (s, 3H), 3.31 (dd, *J* = 13.6, 8.2 Hz, 1H), 3.18 (dd, *J* = 13.6, 6.9 Hz, 1H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 197.4, 170.9, 146.0, 141.0, 137.8, 137.6, 137.0, 136.6, 134.1, 130.0, 129.6, 128.7, 128.3, 128.0, 127.4, 127.2, 126.8, 126.1, 125.6, 122.3, 62.5, 52.9, 43.8, 21.1; HRMS (ESI+) *m/z* calcd. for C₂₈H₂₄NaO₃: 431.1618; found: 431.1611. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); *t*_r = 8.93 and


9.76 min.

Methyl (S)-1-cinnamyl-2-oxo-6-(phenylethynyl)-1,2-dihydronaphthalene-1-carboxylate (2r):




Yield (94%); colorless viscous liquid; $[\alpha]_D^{30} = +226.6$ (c 0.84, CHCl_3); IR (neat) 3027, 2947, 1743, 1666, 1222, 757 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.58 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.54 – 7.50 (m, 3H), 7.41 (d, $J = 9.9$ Hz, 1H), 7.36 – 7.34 (m, 4H), 7.20 – 7.15 (m, 2H), 7.15 – 7.09 (m, 3H), 6.23 – 6.20 (m, 2H), 5.66 (dt, $J = 15.5, 7.6$ Hz, 1H), 3.64 (s, 3H), 3.30 (dd, $J = 13.6, 8.2$ Hz, 1H), 3.15 (dd, $J = 13.6, 7.0$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 196.9, 170.6, 145.1, 138.9, 136.8, 134.3, 133.1, 132.5, 131.6, 129.8, 128.6, 128.4, 128.3, 127.3, 127.1, 126.1, 126.0, 123.4, 122.6, 121.9, 90.8, 87.9, 62.7, 53.0, 43.7; HRMS (ESI+) m/z calcd. for $\text{C}_{29}\text{H}_{22}\text{NaO}_3$: 441.1461; found: 441.1454. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak IA-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 8.71$ and 9.98 min.

Methyl (S)-1-(3,4-dimethoxybenzyl)-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2s):



Yield (96%); light yellow solid; m.p. = 140.1 $^\circ\text{C}$; $[\alpha]_D^{25} = +96.1$ (c 0.61, CHCl_3); IR (neat) 2953, 2841, 1742, 1661, 1516, 1236, 1028, 763 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.50–7.44 (m, 2H), 7.35 (t, $J = 7.3$ Hz, 1H), 7.20 (d, $J = 7.5$ Hz, 1H), 7.11 (d, $J = 9.9$ Hz, 1H), 6.50 (d, $J = 8.2$ Hz, 1H), 6.25 (dd, $J = 8.2, 1.9$ Hz, 1H), 5.93–5.91 (m, 2H), 3.74 (s, 3H), 3.68 (d, $J = 13.5$ Hz, 1H), 3.66 (s, 3H), 3.47 (s, 3H), 3.46 (d, $J = 13.5$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 197.8, 171.1, 147.6, 145.6, 139.6, 130.1, 130.0, 129.6, 128.0, 127.2, 126.6, 125.5, 122.1, 112.5, 110.2, 63.6, 55.5, 55.3, 52.9, 46.3; HRMS (ESI+) m/z calcd. for $\text{C}_{21}\text{H}_{20}\text{NaO}_5$: 375.1203; found: 375.1201. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AS-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 300$ nm); $t_r = 10.79$ and 18.18 min.


Methyl (S)-1-(4-methoxybenzyl)-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2t):



Yield (92%); yellow solid; m.p. = 88.0 $^\circ\text{C}$; $[\alpha]_D^{25} = +87.8$ (c 0.61, CHCl_3); IR (film) 2952, 2837, 1742, 1661, 1513, 1246, 1034, 754 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.48 – 7.42 (m, 2H), 7.34 (t, $J = 8.0$ Hz, 1H), 7.18 (d, $J = 7.5$ Hz, 1H), 7.11 (d, $J = 10.0$ Hz, 1H), 6.50 – 6.46 (m, 4H), 5.93 (d, $J = 10.0$ Hz, 1H), 3.68 (d, $J = 13.5$ Hz, 1H), 3.66 (s, 3H), 3.65 (s, 3H), 3.46 (d, $J = 13.5$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 197.9, 171.2, 158.3, 145.7, 139.5, 130.7, 130.1, 130.0, 129.5, 128.0, 127.2, 126.2, 125.4, 112.9, 63.6, 55.0, 52.9, 45.8; HRMS (ESI+) m/z calcd. for $\text{C}_{20}\text{H}_{18}\text{NaO}_4$: 345.1097; found: 345.1094. The product was analyzed by HPLC to determine the enantiomeric excess: 88% ee (Chiralpak AD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); t_r

= 8.06 and 8.99 min.


Methyl (S)-1-(benzo[d][1,3]dioxol-5-ylmethyl)-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2u):



Yield (95%); yellow solid; m.p. = 131.3 °C; $[\alpha]_D^{23} = +110.4$ (*c* 0.61, CHCl₃); IR (film) 2938, 2890, 1742, 1658, 1487, 1443, 1224, 1038, 930 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.47 (t, *J* = 7.5 Hz, 1H), 7.41 (d, *J* = 7.2 Hz, 1H), 7.35 (t, *J* = 7.2 Hz, 1H), 7.22 (d, *J* = 7.5 Hz, 1H), 7.17 (d, *J* = 10.0 Hz, 1H),

6.42 (d, *J* = 8.0 Hz, 1H), 6.07 (dd, *J* = 8.0, 1.7 Hz, 1H), 6.03 (d, *J* = 1.7 Hz, 1H), 5.97 (d, *J* = 10.0 Hz, 1H), 5.79 (s, 2H), 3.66 (d, *J* = 13.5 Hz, 1H), 3.65 (s, 3H), 3.43 (d, *J* = 13.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 197.7, 171.1, 146.7, 146.2, 145.7, 139.3, 130.2, 129.9, 129.6, 128.2, 127.9, 127.1, 125.4, 123.0, 110.0, 107.5, 100.6, 63.5, 52.9, 46.2; HRMS (ESI+) *m/z* calcd. for C₂₀H₁₆NaO₅: 359.0890; found: 359.0883. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 300 nm); *t_r* = 9.42 and 12.12 min.


Methyl (S,E)-1-(2-methyl-3-phenylallyl)-2-oxo-1,2-dihydronaphthalene-1-carboxylate (2v):



Yield (71%); colorless viscous liquid; $[\alpha]_D^{25} = +40.5$ (*c* 0.84, CHCl₃); IR (neat) 3022, 2951, 1742, 1663, 1223, 762 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.47 – 7.42 (m, 2H), 7.40 – 7.35 (m, 3H), 7.22 – 7.18 (m, 2H), 7.13 – 7.10 (m, 1H), 6.90 – 6.88 (m, 2H), 6.22 (d, *J* = 9.9 Hz, 1H), 5.89 (s, 1H), 3.63 (s, 3H), 3.39 (d,

J = 13.3 Hz, 1H), 3.20 (d, *J* = 13.3 Hz, 1H), 1.36 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 197.8, 171.2, 145.9, 139.6, 137.7, 132.2, 130.2, 129.74, 129.72, 128.6, 128.1, 127.8, 127.4, 126.1, 125.7, 62.8, 53.0, 50.5, 19.3; HRMS (ESI+) *m/z* calcd. for C₂₂H₂₀NaO₃: 335.1305; found: 335.1308. The product was analyzed by HPLC to determine the enantiomeric excess: 88% ee (Chiralpak AS-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); *t_r* = 6.81 and 8.00 min.

Methyl (+)-(R,E)-3-oxo-4-phenyl-4-(3-(thiophen-3-yl)allyl)-3,4-dihydronaphthalene-2-carboxylate (4a):




Yield (52%); light yellow viscous liquid; $[\alpha]_D^{23} = +61.7$ (*c* 1.20, CHCl₃); IR (neat) 3020, 2949, 1734, 1216, 756 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.18 (s, 1H), 7.50 (t, *J* = 6.8 Hz, 2H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.30 (d, *J* = 7.9 Hz, 1H), 7.26 – 7.21 (m, 3H), 7.12 (dd, *J* = 4.9, 3.0 Hz, 1H), 7.07 (d, *J* = 7.0 Hz, 2H), 6.91 (dd, *J* = 7.7, 3.7 Hz, 2H), 6.34 (d, *J* = 15.8 Hz, 1H), 5.74 – 5.52 (m,

1H), 3.81 (s, 3H), 3.77 (dd, *J* = 13.9, 7.3 Hz, 1H), 3.06 (dd, *J* = 13.6, 7.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 196.3, 165.0, 150.5, 145.8, 141.9, 139.7, 131.9, 131.5, 129.6, 129.3, 128.6, 128.1, 127.6, 127.4, 125.7, 125.6, 124.9, 124.3, 121.3, 61.6, 52.3, 42.4; HRMS (ESI+) *m/z* calcd. for


C₂₅H₂₀NaO₃S: 423.1025; found: 423.1026; The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak AS-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); t_r = 11.08 and 14.26 min. The absolute configuration of **4a** was speculated based on the proposed transition state shown in Figure 1b.

Methyl (-)-(S,E)-4-allyl-3-oxo-4-(3-(thiophen-3-yl)allyl)-3,4-dihydronaphthalene-2-carboxylate (4b):



Yield (56%); light yellow viscous liquid; [α]_D²² = -14.3 (*c* 1.20, CHCl₃); IR (neat) 3006, 2950, 1734, 1676, 1217, 759 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.12 (s, 1H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.44 (d, *J* = 7.5 Hz, 1H), 7.35 (t, *J* = 7.4 Hz, 1H), 7.13 – 7.12 (m, 1H), 6.91 (d, *J* = 4.0 Hz, 2H), 6.22 (d, *J* = 15.7 Hz, 1H), 5.57 – 5.51 (m, 1H), 5.35 – 5.27 (m, 1H), 4.87 (d, *J* = 17.0 Hz, 1H), 4.82 (d, *J* = 10.2 Hz, 1H), 3.86 (s, 3H), 3.04 (dd, *J* = 13.6, 7.6 Hz, 1H), 2.98 (dd, *J* = 13.6, 7.2 Hz, 1H), 2.68 (dd, *J* = 13.6, 7.6 Hz, 1H), 2.61 (dd, *J* = 13.6, 7.2 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 198.0, 165.3, 150.5, 145.2, 139.6, 132.2, 131.8, 131.6, 129.2, 127.8, 127.3, 126.3, 125.6, 124.9, 123.7, 121.3, 118.6, 57.8, 52.3, 45.5, 44.7; HRMS (ESI+) *m/z* calcd. for C₂₂H₂₀NaO₃: 355.1310; found: 355.12306; The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralpak OD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm); t_r = 9.09 and 11.97 min. The absolute configuration of **4b** was speculated based on the proposed transition state shown in Figure 1b.


7. Synthetic Application of 2a



To 1 mL of MeOH were added **2a** (63.6 mg, 0.2 mmol, 92% ee) and CeCl₃·7H₂O (1.1 mg, 0.22 mmol), then the reaction system was cooled to -78 °C. After which NaBH₄ (8.4 mg, 0.22 mmol) was added slowly to the solution. After stirring at -78 °C temperature for 2 h, the solvent was evaporated and the residue was purified by column chromatography to give **5** in 88% yield, which was then directly analyzed by HPLC to determine the enantiomeric excess.



Methyl (1S,2R)-1-cinnamyl-2-hydroxy-1,2-dihydronaphthalene-1-carboxylate (5):


Yield (88%); colorless viscous liquid; [α]_D²³ = +69.0 (*c* 0.73, CHCl₃); IR (neat) 3447, 3024, 2950, 1730, 1224, 967, 744 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.28 – 7.18 (m, 8H), 7.11 (d, *J* = 6.8 Hz,



1H), 6.46 (d, $J = 9.7$ Hz, 1H), 6.34 – 6.26 (m, 2H), 6.08 (dd, $J = 9.6, 3.5$ Hz, 1H), 5.10 (d, $J = 6.2$ Hz, 1H), 3.75 (s, 3H), 3.03 (dd, $J = 13.5, 5.6$ Hz, 1H), 2.96 (dd, $J = 13.5, 5.6$ Hz, 1H), 1.86 (d, $J = 8.1$ Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 174.4, 137.4, 134.9, 132.8, 132.1, 130.7, 128.4, 127.8, 127.4, 127.1,

127.1, 126.8, 126.1, 70.4, 57.2, 52.4, 35.0; HRMS (ESI+) m/z calcd. for C₂₁H₂₀NaO₃: 343.1305; found: 343.299. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak AD-3, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 6.78$ and 8.15 min.





8. SX-ray Structure of Product (*S*)-2I and Cu(II) Complex






Figure S1. X-ray structure of (*S*)-2I

Crystal data for (*S*)-2I: $C_{27}H_{20}Cl_2O_3$, $T = 123$ K, Orthorhombic, space group $P212121$ (#19), $a = 7.6102(8)$, $b = 10.7051(11)$, $c = 27.326(3)$ Å, $V = 2226.2(4)$ Å³, $Z = 4$, $\lambda(\text{MoK}\alpha) = 0.71073$ Å, 4973 reflections collected, and 294 parameters were used for the solution of the structure, final $R_1 = 0.0256$ and $wR_2 = 0.0671$, $\text{GOF} = -0.005(9)$, CCDC 1865509 contains the supplementary crystallographic data for this paper.


a) bottom-up view



b) top view



c) side view-1



d) side view-2




Figure S2. X-ray structure of Cu(II) complex


Crystal data for Cu(II) complex: $C_{50}H_{64}CuF_6N_4O_8S_2$, $T = 123$ K, orthorhombic, space group


P212121, $a = 14.293(3)$, $b = 16.823(3)$, $c = 21.700(5)$ Å, $V = 5217.8(19)$ Å³, $Z = 4$, $\lambda(\text{MoK}\alpha) = 0.71075$ Å, 11938 reflections collected, and 648 parameters were used for the solution of the structure, final $R_1 = 0.0834$ and $wR_2 = 0.1397$, GOF = 1.107, CCDC 1865510 contains the supplementary crystallographic data for this paper.


9. References


1. (a) Aoyama, T.; Okutome, T.; Nakayama, T.; Yaegashi, T.; Matsui, R.; Nunomura, S.; Kurumi, M.; Sakurai, Y.; Fujii, S. *Chem. Pharm. Bull.* **1985**, *33*, 1458–1471. (b) Yin, Q.; Wang, S.-G.; Liang, X.-W.; Gao, D.-W.; Zheng, J.; You, S.-L., *Chem. Sci.* **2015**, *6*, 4179–4183.
2. Tayama, E.; Naganuma, N.; Iwamoto, H.; Hasegawa, E. *Chem. Comm.* **2014**, *50*, 6860–6862.
3. M. Amézquita-Valencia, H. Alper, *Org. Lett.* **2014**, *16*, 5827–5829.
4. P. Wawrzyniak, M. K. Kindermann, G. Thede, R. Thede, P. G. Jones, S. Enthaler, K. Junge, M. Beller, J. W. Heinicke, *Eur. J. Inorg. Chem.* **2017**, *2017*, 2762–2773.
5. M. Uyanik, N. Sahara, K. Ishihara, *Eur. J. Org. Chem.*, DOI: 10.1002/ejoc.201801063


10. ¹H NMR and ¹³C NMR Spectra













































































































































































































































































































































































H-H COSY



H-H NOESY




11. HPLC Chromatograms



11/2/2017 11:01:22 AM Page 1 / 1



=== Shimadzu LabSolutions ===

Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-5-3a-rac.kd		
Method Name	:	C4-20-80-1-15m.in.km		
Batch Name	:	LY-5-3a.kb		
Vial	:	1-20		
Inj Volume	:	1 uL		
Acquisition Date	:	2017/10/05 16:23:52	分析者	: System Administrator
Modified Date	:	2017/10/05 16:58:21	解析者	: System Administrator




PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.915	962268	94320	49.519
2	8.732	980963	79701	50.481
Total		1943230	174021	100.000




D:\Data\LY\data\LY-5-3a-rac.kd





=== Shimadzu LabSolutions ===


Sample ID	:	:	
Data Name	:	:	LY-6-5%cat.kd
Method Name	:	:	安定化C4-20-80-1-20m in.km
Batch Name	:	:	LY-6-5%cat.kb
Vial	:	:	1-21
Inj Volume	:	:	1 ul
Acquisition Date	:	:	2018/05/28 10:13:55
Modified Date	:	:	2018/05/28 10:33:58
		サンプルタイプ	:Unknown
		分析者	:System Administrator
		解析者	:System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.827	265476	23727	4.065
2	8.653	6265030	464021	95.935
Total		6530506	487749	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3b-rac.kd
 Method Name :C4-20-80-1-15m i.km
 Batch Name :LY-5-3b.kb
 Vial :1-20
 Inj Volume :1 uL
 Acquisition Date :2017/10/04 19:36:20
 Modified Date :2017/10/04 20:09:52


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 272nm

Peak No.	RT (min)	Area	Height	% Area
1	6.272	450135	48008	49.534
2	6.777	458608	45530	50.466
Total		908743	93538	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3b.kcd
 Method Name :C4-20-80-1-15m.in.km
 Batch Name :LY-5-3b.kb
 Vial :1-21
 Injection Volume :1 uL
 Acquisition Date :2017/10/04 19:51:47
 Modified Date :2017/11/02 11:19:40


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 272nm

Peak No.	RT (min)	Area	Height	% Area
1	6.242	30269	3579	2.684
2	6.737	1097493	108603	97.316
Total		1127762	112182	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3c-rac.kd
 Method Name :C4-20-80-1-15m i.km
 Batch Name :LY-5-3c.kb
 Vial :1-18
 Inj Volume :1 uL
 Acquisition Date :2017/10/04 18:25:01
 Modified Date :2017/11/02 11:28:34


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.545	1794225	181395	49.647
2	7.998	1819723	154470	50.353
Total		3613948	335865	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3c.kd
 Method Name :C4-20-80-1-15m i.km
 Batch Name :LY-5-3c.kb
 Vial :1-19
 Inj Volume :1 uL
 Acquisition Date :2017/10/04 18:40:25
 Modified Date :2017/10/04 19:27:42


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.564	66673	7256	4.091
2	8.022	1563238	132710	95.909
Total		1629911	139966	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3d-rac.kd
 Method Name :C4-20-80-1-15m i.km
 Batch Name :LY-5-3d.kb
 Vial :1-18
 Injection Volume :1 uL
 Acquisition Date :2017/10/03 23:37:15
 Modified Date :2017/10/04 10:43:04


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.722	287877	28421	50.393
2	10.437	283392	20292	49.607
Total		571268	48713	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3d.kcd
 Method Name :C4-20-80-1-15m i.km
 Batch Name :LY-5-3d.kb
 Vial :1-19
 Inj Volume :1 uL
 Acquisition Date :2017/10/03 23:52:40
 Modified Date :2017/10/16 11:11:42


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	6.670	163485	17533	5.018
2	10.293	3094691	215581	94.982
Total		3258176	233115	100.000







=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-5-3g-rac.kd		
Method Name	:	C4-20-80-1-20m i.km		
Batch Name	:	LY-5-3g.kb		
Vial	:	1-20		
Inj Volume	:	1 uL		
Acquisition Date	:	2017/10/18 12:30:32	分析者	: System Administrator
Modified Date	:	2017/10/18 14:38:47	解析者	: System Administrator



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	8.054	362225	31340	49.947
2	11.378	363001	23380	50.053
Total		725226	54720	100.000







=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-5-3g.kd		
Method Name	:	C4-20-80-1-20m.n.km		
Batch Name	:	LY-5-3g.kb		
Vial	:	1-21		
Inj Volume	:	1 uL		
Acquisition Date	:	2017/10/18 12:50:57	分析者	: System Administrator
Modified Date	:	2017/10/31 20:46:19	解析者	: System Administrator



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	8.047	57733	5418	4.505
2	11.362	1223770	78413	95.495
Total		1281502	83831	100.000







=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-5-3e-rac.kd		
Method Name	:	C4-20-80-1-15m i.km		
Batch Name	:	LY-5-3e.kb		
Vial	:	1-18		
Inj Volume	:	1 uL		
Acquisition Date	:	2017/10/05 17:35:14	分析者	: System Administrator
Modified Date	:	2017/10/05 19:31:52	解析者	: System Administrator



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	7.724	494481	45546	49.788
2	10.615	498700	34401	50.212
Total		993181	79947	100.000







=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-5-3e.kd		
Method Name	:	C4-20-80-1-15m.n.km		
Batch Name	:	LY-5-3e.kb		
Vial	:	1-19		
Inj Volume	:	1 uL		
Acquisition Date	:	2017/10/05 17:50:39	分析者	: System Administrator
Modified Date	:	2017/10/05 19:31:36	解析者	: System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	7.776	65545	6539	3.919
2	10.728	1606866	108680	96.081
Total		1672411	115219	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3i-rac.kd
 Method Name :安定化C4-20-80-1-20m.in.km
 Batch Name :LY-5-3ikb
 Vial :1-21
 Inj Volume :1 uL
 Acquisition Date :2018/05/25 16:09:55
 Modified Date :2018/05/25 16:29:59


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	7.601	127764	10759	50.189
2	8.349	126801	10055	49.811
Total		254564	20814	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3ikd
 Method Name :安定化C4-20-80-1-20m.in.lcm
 Batch Name :LY-5-3ikb
 Vial :1-22
 Injection Volume :1 uL
 Acquisition Date :2018/05/25 15:49:37
 Modified Date :2018/05/25 16:09:40


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	7.605	15259	1357	4.167
2	8.348	350911	27474	95.833
Total		366170	28831	100.000






=== Shimadzu LabSolutions ===



Sample :
 ID :
 Data Name :LY-5-3h-rac.kd
 Method Name :C4-20-80-1-20m in.km
 Batch Name :LY-5-3h.kb
 Vial :1-18
 Inj Volume :1 uL
 Acquisition Date :2017/10/12 21:41:32
 Modified Date :2017/10/13 15:01:40


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.765	486146	38285	50.458
2	13.438	477312	26397	49.542
Total		963458	64682	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3h.kd
 Method Name :C4-20-80-1-20m in.km
 Batch Name :LY-5-3h.kb
 Vial :1-19
 Inj Volume :1 uL
 Acquisition Date :2017/10/12 22:01:58
 Modified Date :2017/10/13 14:54:16


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.768	114650	10013	3.931
2	13.428	2802111	154136	96.069
Total		2916760	164149	100.000






=== Shimadzu LabSolutions ===

Sample :
 ID :
 Data Name :LY-5-31-rac001.kd
 Method Name :C4-20-80-1-20m n.km
 Batch Name :LY-5-31.kb
 Vial :1-18
 Inj Volume :1 uL
 Acquisition Date :2017/11/04 18:58:30
 Modified Date :2017/11/04 19:18:33


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	7.333	135221	10621	52.241
2	9.937	123619	6221	47.759
Total		258841	16842	100.000


UVスペクトル



=== Shimadzu LabSolutions ===



Sample :
 ID :
 Data Name : LY-5-3D03.kcd
 Method Name : C4-20-80-1-20m in.km
 Batch Name : LY-5-3F-1.kb
 Vial : 1-62
 Inj Volume : 1 uL
 Acquisition Date : 2018/03/16 13:18:52
 Modified Date : 2018/03/16 14:07:21


サンプルタイプ : Unknown
 分析者 : System Administrator
 解析者 : System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	7.686	78221	5876	2.044
2	10.625	3748648	200591	97.956
Total		3826869	206467	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3n001.kd
 Method Name :C4-20-80-1-20m in.km
 Batch Name :LY-5-3n.kb
 Vial :1-63
 Inj Volume :1 uL
 Acquisition Date :2018/03/02 02:43:36
 Modified Date :2018/03/02 04:43:39


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.467	348833	24301	49.764
2	13.122	352148	15927	50.236
Total		700981	40229	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-3n-rac001.kd
 Method Name :C4-20-80-1-20m n.km
 Batch Name :LY-5-3n.kb
 Vial :1-64
 Inj Volume :1 uL
 Acquisition Date :2018/03/02 04:50:2
 Modified Date :2018/03/12 15:26:22


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.485	34432	2660	3.084
2	13.161	1082004	47925	96.916
Total		1116436	50585	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-1a-rac.kd
 Method Name :C3-80-20-1m F-20m in.km
 Batch Name :LY-5-3x.kb
 Vial :1-18
 Injection Volume :1 uL
 Acquisition Date :2017/10/11 21:42:39
 Modified Date :2017/10/11 22:02:42


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.654	320470	30647	50.823
2	9.189	310094	23635	49.177
Total		630565	54283	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-1a.kd
 Method Name :C3-80-20-1m F20m in.km
 Batch Name :LY-5-3x.kb
 Vial :1-19
 Injection Volume :1 uL
 Acquisition Date :2017/10/11 22:03:05
 Modified Date :2017/10/11 22:23:08


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.666	27512	2647	3.056
2	9.218	872661	66544	96.944
Total		900173	69191	100.000






11/13/2017 8:33:14 PM Page 1 / 1



=== Shimadzu LabSolutions ===

Sample ID	:	:		
Data Name	:	LY-5-1b-rac.kd		
Method Name	:	C3-80-20-1m F-20m i.n.km		
Batch Name	:	LY-5-1b.kb		
Vial	:	1-18	サンプルタイプ	: Unknown
Inj Volume	:	1 ul		
Acquisition Date	:	2017/11/01 14:06:09	分析者	: System Administrator
Modified Date	:	2017/11/13 20:33:01	解析者	: System Administrator




PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.014	224968	17545	50.266
2	10.857	222589	13394	49.734
Total		447557	30939	100.000




D:\Data\LY\data\LY-5-1b-rac.kd





11/13/2017 8:31:26 PM Page 1 / 1

=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:		分析者	: System Administrator
Data Name	:	LY-5-1b.kd	解析者	: System Administrator
Method Name	:	C3-80-20-1m F20m in.km		
Batch Name	:	LY-5-1b.kb		
Vial	:	1-19		
Inj Volume	:	1 ul		
Acquisition Date	:	2017/11/01 14:26:33		
Modified Date	:	2017/11/01 15:05:56		



Peak No.	RT (min)	Area	Height	% Area
1	8.016	881458	68974	95.205
2	10.860	44399	3003	4.795
Total		925857	71977	100.000




D:\Data\LY\data\LY-5-1b.kd



=== Shimadzu LabSolutions ===


Sample :
 D :
 Data Name :LY-5-1d-rac.kd
 Method Name :C2-20-80-1-20m in.km
 Batch Name :LY-5-1d-1.kb
 Vial :1-18
 Inj Volume :1 uL
 Acquisition Date :2017/11/20 22:32:58
 Modified Date :2017/11/20 22:53:01


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 290nm

Peak No.	RT (min)	Area	Height	% Area
1	5.606	220751	19172	49.563
2	6.056	224645	17254	50.437
Total		445395	36426	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-1d.kd
 Method Name :C2-20-80-1-20m in.km
 Batch Name :LY-5-1d-1.kb
 Vial :1-19
 Inj Volume :1 uL
 Acquisition Date :2017/11/20 22:53:32
 Modified Date :2017/11/21 21:53:03


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 290nm


Peak No.	RT (min)	Area	Height	% Area
1	5.627	1888999	161852	84.027
2	6.079	359074	27495	15.973
Total		2248073	189347	100.000







=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:		分析者	: System Administrator
Data Name	:	LY-5-130a-rac.kd	解析者	: System Administrator
Method Name	:	C4-20-80-1-20m.in.km		
Batch Name	:	LY-5-130a.kb		
Vial	:	1-18		
Inj Volume	:	1 ul		
Acquisition Date	:	2017/11/06 10:52:03		
Modified Date	:	2017/11/06 11:12:06		



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	7.339	194816	15741	50.325
2	9.086	192296	10382	49.675
Total		387111	26123	100.000






=== Shimadzu LabSolutions ===


Sample :
 ID :
 Data Name :LY-5-130a.lcd
 Method Name :C4-20-80-1-20m in.km
 Batch Name :LY-5-130a.kb
 Vial :1-19
 Inj Volume :1 ul
 Acquisition Date :2017/11/06 11:12:29
 Modified Date :2017/11/06 11:32:31


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	7.321	108106	9406	3.447
2	9.036	3028153	162708	96.553
Total		3136260	172113	100.000







=== Shimadzu LabSolutions ===


Sample :
 ID :
 Data Name :LY-5-130b-rac.kd
 Method Name :C4-20-80-1-20m in.km
 Batch Name :LY-5-130b.kb
 Vial :1-18
 Inj Volume :1 ul
 Acquisition Date :2017/12/14 16:04:51
 Modified Date :2017/12/14 17:04:45
 サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	7.883	311886	24649	50.439
2	16.962	306459	12228	49.561
Total		618344	36878	100.000







=== Shimadzu LabSolutions ===


Sample ID	:	:	サンプルタイプ	: Unknown
Data Name	:	: LY-5-130b.lcd	分析者	: System Administrator
Method Name	:	: C4-20-80-1-20m in.km	解析者	: System Administrator
Batch Name	:	: LY-5-130b.kb		
Vial	:	: 1-19		
Inj Volume	:	: 1 uL		
Acquisition Date	:	: 2017/12/14 16:25:16		
Modified Date	:	: 2017/12/14 17:05:55		



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	7.910	203379	16509	9.291
2	16.806	1985642	80097	90.709
Total		2189021	96606	100.000







=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:		分析者	: System Administrator
Data Name	:	LY-5-130g-rac.kd	解析者	: System Administrator
Method Name	:	C3-80-20-1m f-20m in.km		
Batch Name	:	LY-5-130g.kb		
Vial	:	1-18		
Inj Volume	:	1 ul		
Acquisition Date	:	2017/12/23 16:17:31		
Modified Date	:	2017/12/23 16:37:33		



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	13.383	1184174	63605	49.935
2	15.088	1187247	56507	50.065
Total		2371421	120112	100.000






12/25/2017 10:53:58 AM Page 1 / 1

=== Shimadzu LabSolutions ===



Sample :
 ID :
 Data Name :LY-5-130g.kd
 Method Name :C3-80-20-1m f-20m in.km
 Batch Name :LY-5-130g.kb
 Vial :1-19
 Injection Volume :1 ul
 Acquisition Date :2017/12/23 16:37:55
 Modified Date :2017/12/23 16:37:58

サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator




PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	13.440	81218	4794	5.633
2	15.148	1360501	64755	94.367
Total		1441719	69550	100.000




D:\Data\LY\data\LY-5-130g.kd



=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-130d-rac.kd
 Method Name :C3-80-20-1m I-20m in.km
 Batch Name :LY-5-130d.kb
 Vial :1-18
 Inj Volume :1 uL
 Acquisition Date :2017/12/15 12:42:13
 Modified Date :2017/12/15 13:36:27

サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator




PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.893	631616	43199	49.870
2	9.708	634918	41978	50.130
Total		1266534	85177	100.000




D:\data\LY\data\LY-5-130d-rac.kd



=== Shimadzu LabSolutions ===


Sample :
 D :
 Data Name :LY-5-130d.kcd
 Method Name :C3-80-20-1m I-20m in.km
 Batch Name :LY-5-130d.kcb
 Vial :1-19
 Inj Volume :1 uL
 Acquisition Date :2017/12/15 13:02:37
 Modified Date :2017/12/15 13:36:18

サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator





PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.930	1611821	110398	96.447
2	9.763	59369	4339	3.553
Total		1671190	114737	100.000



UVスペクトル






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-130c-rac.kd
 Method Name :C4-20-80-1-20m h.km
 Batch Name :LY-5-130c.kb
 Vial :1-18
 Inj Volume :1 uL
 Acquisition Date :2017/12/14 20:59:44
 Modified Date :2017/12/14 21:19:46


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.692	1029843	69996	50.576
2	9.971	1006395	48478	49.424
Total		2036238	118475	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-130c.kd
 Method Name :C4-20-80-1-20m i.km
 Batch Name :LY-5-130c.kb
 Vial :1-19
 Inj Volume :1 uL
 Acquisition Date :2017/12/14 21:20:09
 Modified Date :2017/12/14 21:40:11


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.713	70842	5415	3.454
2	9.984	1980226	96241	96.546
Total		2051068	101656	100.000






=== Shimadzu LabSolutions ===


Sample :
 D :
 Data Name :LY-6-102c-rac.kd
 Method Name :C2-20-80-1-20m h.km
 Batch Name :LY-6-102c.kb
 Vial :1-61
 Inj Volume :1 uL
 Acquisition Date :2018/06/12 22:39:17
 Modified Date :2018/06/13 10:01:41

サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator




PDA Ch1 300nm

Peak No.	RT (min)	Area	Height	% Area
1	10.748	171078	8258	50.328
2	18.130	168849	4423	49.672
Total		339926	12682	100.000




D:\data\LY\data\LY-6-102c-rac.kd



=== Shimadzu LabSolutions ===


Sample :
 D :
 Data Name :LY-6-102c.kd
 Method Name :C2-20-80-1-20m in.km
 Batch Name :LY-6-102c.kb
 Vial :1-62
 Inj Volume :1 uL
 Acquisition Date :2018/06/12 22:59:50
 Modified Date :2018/06/13 10:02:01


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 300nm


Peak No.	RT (min)	Area	Height	% Area
1	10.786	453985	21559	97.099
2	18.178	13563	412	2.901
Total		467549	21970	100.000





=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-6-102b-rac001.kd		
Method Name	:	C3-80-20-1m I-20m n.km		
Batch Name	:	LY-6-102b.kb		
Vial	:	1-48		
Inj Volume	:	1 uL		
Acquisition Date	:	2018/06/14 18:40:48	分析者	: System Administrator
Modified Date	:	2018/06/14 20:18:46	解析者	: System Administrator




PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	8.077	107981	9498	50.281
2	9.010	106773	8639	49.719
Total		214754	18138	100.000

保持時間 : 8.077 min



UVスペクトル 保持時間 : 9.010 min






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-6-102b001.kcd
 Method Name :C3-80-20-1m f-20m in.km
 Batch Name :LY-6-102b.kcb
 Vial :1-49
 Inj Volume :1 uL
 Acquisition Date :2018/06/14 19:01:13
 Modified Date :2018/06/14 20:19:28

サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator




PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.060	167113	14765	93.869
2	8.989	10915	974	6.131
Total		178028	15739	100.000




D:\Data\LY\data\LY-6-102b001.kcd





=== Shimadzu LabSolutions ===

Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-6-102a-rac.kd		
Method Name	:	C3-80-20-1m I-20m in.km		
Batch Name	:	LY-6-102.kb		
Vial	:	1-46		
Inj Volume	:	1 uL		
Acquisition Date	:	2018/06/12 19:56:20	分析者	: System Administrator
Modified Date	:	2018/06/12 21:45:28	解析者	: System Administrator



Peak No.	RT (min)	Area	Height	% Area
1	9.376	228066	17993	50.041
2	12.033	227696	14441	49.959
Total		455761	32434	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-6-102a.kcd
 Method Name :C3-80-20-1m I-20m in.km
 Batch Name :LY-6-102.kcb
 Vial :1-47
 Inj Volume :1 uL
 Acquisition Date :2018/06/12 20:16:45
 Modified Date :2018/06/12 21:46:55


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 300nm

Peak No.	RT (min)	Area	Height	% Area
1	9.421	805445	63233	96.256
2	12.118	31327	2029	3.744
Total		836772	65263	100.000






=== Shimadzu LabSolutions ===


Sample :
 D :
 Data Name :LY-5-1c-rac001.kd
 Method Name :C2-20-80-1-20m n.km
 Batch Name :LY-5-1c.kb
 Vial :1-18
 Inj Volume :1 uL
 Acquisition Date :2017/11/13 19:38:05
 Modified Date :2017/11/13 20:22:38


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.811	349496	22811	50.149
2	7.987	347423	16876	49.851
Total		696919	39686	100.000






=== Shimadzu LabSolutions ===



Sample :
 D :
 Data Name :LY-5-1c001.kd
 Method Name :C2-20-80-1-20m in.km
 Batch Name :LY-5-1c.kb
 Vial :1-19
 Inj Volume :1 uL
 Acquisition Date :2017/11/13 19:58:36
 Modified Date :2018/03/01 21:05:36


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.813	2077139	136531	94.102
2	7.996	130190	7069	5.898
Total		2207329	143600	100.000






=== Shimadzu LabSolutions ===



Sample :
D
 Data Name :LY-7-75-RAC.kcd
 Method Name :C2-20-80-1-30m n.km
 Batch Name :LY-7-75.kb
 Vial :1-61
 Inj Volume :1 uL
 Acquisition Date :2018/10/26 18:36:38
 Modified Date :2018/10/26 21:22:32


サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	11.081	302759	8659	50.688
2	14.105	294539	6253	49.312
Total		597299	14912	100.000







=== Shimadzu LabSolutions ===


Sample	:		
D	:		
Data Name	:	LY-7-75-92EE.kd	
Method Name	:	C2-20-80-1-20m in.km	
Batch Name	:	LY-7-75.kb	
Vial	:	-1	サンプルタイプ : Unknown
Inj Volume	:	1 uL	
Acquisition Date	:	2018/11/07 15:58:23	分析者 : System Administrator
Modified Date	:	2018/11/07 16:20:04	解析者 : System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	11.079	597031	17600	96.150
2	14.263	23903	525	3.850
Total		620934	18125	100.000






11/12/2018 2:23:04 PM Page 1 / 1


=== Shimadzu LabSolutions ===

Sample ID	:	:		
Data Name	:	LY-7-110-RAC-od.kd		
Method Name	:	C1-20-80-1-20min.km		
Batch Name	:	LY-7-110-RAC.kb	サンプルタイプ	:Unknown
Vial	:	1-61		
Inj Volume	:	1 uL	分析者	:System Administrator
Acquisition Date	:	2018/11/08 10:28:54	解析者	:System Administrator
Modified Date	:	2018/11/09 11:33:52		




PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	8.949	203401	13634	50.713
2	11.807	197679	8456	49.287
Total		401079	22090	100.000




D:\Data\LY\data\LY-7-110-RAC-od.kd




=== Shimadzu LabSolutions ===


Sample	:		サンプルタイプ	: Unknown
D	:			
Data Name	:	LY-7-110.kd		
Method Name	:	C1-20-80-1-20m in.km	分析者	: System Administrator
Batch Name	:	LY-7-110.kb	解析者	: System Administrator
Vial	:	1-61		
Inj Volume	:	1 uL		
Acquisition Date	:	2018/11/08 22:33:36		
Modified Date	:	2018/11/09 11:33:38		



PDA Ch1 254nm


Peak No.	RT (min)	Area	Height	% Area
1	9.089	37835	2603	4.691
2	11.972	768730	32338	95.309
Total		806565	34941	100.000







=== Shimadzu LabSolutions ===

Sample ID	:	:	サンプルタイプ	: Unknown
Data Name	:	: LY-5-110-rac.kd	分析者	: System Administrator
Method Name	:	: C3-80-20-1m f-20m in.km	解析者	: System Administrator
Batch Name	:	: LY-5-110.kb		
Vial	:	: 1-32		
Inj Volume	:	: 1 ul		
Acquisition Date	:	: 2018/02/02 11:02:21		
Modified Date	:	: 2018/02/02 11:22:24		




PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.729	1211638	111252	41.099
2	7.299	276803	23681	9.389
3	8.050	1200750	97013	40.730
4	9.034	258889	19230	8.782
Total		2948081	251176	100.000




D:\Data\LY\data\LY-5-110-rac.kd



=== Shimadzu LabSolutions ===

Sample :
 D :
 Data Name :LY-5-110.kd
 Method Name :C3-80-20-1m F20m in.km
 Batch Name :LY-5-110.kb
 Vial :1-33
 Inj Volume :1 uL
 Acquisition Date :2018/02/02 11:22:47
 Modified Date :2018/02/02 11:42:50

サンプルタイプ :Unknown
 分析者 :System Administrator
 解析者 :System Administrator



PDA Ch1 254nm

Peak No.	RT (min)	Area	Height	% Area
1	6.783	2081513	189743	95.803
2	8.153	91177	7321	4.197
Total		2172690	197064	100.000

